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Abstract
Clear cell renal cell carcinoma (ccRCC) is characterized by Von Hippel-Lindau (VHL)deficiency, resulting in pseudohypoxic, angiogenic and glycolytic tumours. Hydrogen sulfide
(H2S) is an endogenously-produced gasotransmitter that accumulates under hypoxia and has
been shown to be pro-angiogenic and cytoprotective in cancer. It was hypothesized that H2S
levels are elevated in VHL-deficient ccRCC, contributing to survival, metabolism, and
angiogenesis. Using H2S-specific probes, it was found that H2S levels were higher in VHLdeficient ccRCC cell lines compared to cells with wild-type VHL. Inhibition of H2Sproducing enzymes could reduce the proliferation, metabolism and survival of ccRCC cell
lines, as determined by live-cell imaging, XTT/ATP assay, and flow cytometry, respectively.
Using the chorioallantoic membrane angiogenesis model, it was found that systemic
inhibition of endogenous H2S production was able to decrease vascularization of VHLdeficient ccRCC xenografts. Endogenous H2S production is an attractive new target in
ccRCC due to its involvement in multiple aspects of disease.

Keywords
Clear cell renal cell carcinoma; hydrogen sulfide; cell hypoxia; angiogenesis; cell
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1. Introduction
1.1 Renal Cell Carcinoma (RCC)
As with other cancers, kidney cancer can be categorized into multiple sub-types. The
most prevalent form of kidney cancer is known as renal cell carcinoma (RCC) and
accounts for 80-90% of kidney cancer cases and 2-3% of all cancer cases (1). RCC arises
as a result of mutations to the epithelial cells of nephrons – the functional units of the
kidney. Increasing incidence rates for RCC have been reported over the last few decades,
and this has been attributed to popular usage of CT and ultrasound imaging for other
conditions (2). Some studies suggest that increasing incidence of RCC risk factors like
diabetes, hypertension and obesity may also be responsible for the increasing prevalence
of RCC, though these conditions have not been established as true etiological factors of
RCC (3-7). Despite the increase in incidental detection of RCC and timely removal of
the primary tumour, the cancer-specific mortality rate of RCC remains high at 30-40%
(2). This high mortality rate is due to the high likelihood – approximately 20-30% – that
the disease has already metastasized at the time of detection (2). Unfortunately,
metastatic RCC (mRCC) has proven to be highly resistant to both chemotherapy and
radiation therapy, and this resistance contributes to the high mortality rates observed (8).
While it is true that novel growth-targeting therapies offer improvements in overall
survival (OS) and progression-free survival (PFS), these therapies do not offer a cure for
the disease (1).
RCC can be further sub-divided into various histotypes based on tumour morphology,
genetic signature, and clinical manifestation. The area of the nephron from which the
tumour arises (proximal tubule, distal tubule, collecting duct, etc.) also plays a role in the
classification of RCCs (9). Whether sporadic or inherited, genetic mutations in RCC
often affect pathways involved in oxygen, nutrient, or energy sensing and for this reason
RCC is often described as a metabolic disease (9,10). In today’s clinical landscape of
targeted therapies, identifying key targets within these metabolic pathways is essential
(1,11). While most subtypes of RCC seem to subvert cellular metabolic pathways to their
advantage, the specific pathways that are disrupted in each subtype, and indeed in each
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patient, varies widely (12). Identifying pathways that are commonly disrupted in RCC
and developing therapies that target these pathways has proven to be an effective
treatment strategy in RCC in that they improved PFS when compared to chemotherapy
and radiation therapy (12).

1.1.1

Clear Cell RCC and Von Hippel-Lindau

The most common histotype of RCC is the clear cell histotype (ccRCC) and accounts for
75-80 % of all RCC cases (2). The characteristic “clear” cytoplasm of these cancer cells
is due to increased production and accumulation of deposits containing cholesterol esters,
fatty acids, and glycogen which makes histological identification relatively easy. While
the exact mechanisms that lead to accumulation of these lipid deposits are still being
investigated, we do know that a crucial step in this process is inactivation of a key tumour
suppressor – the Von Hippel-Lindau (VHL) tumour suppressor (13,14). VHL is an E3
ubiquitin ligase that is crucial in targeting certain cellular proteins for proteasomal
degradation in response to changing cellular conditions, and is inactivated in the large
majority (90%) of ccRCC tumours (1,15). When VHL is expressed in its wild-type form
(VHL WT), it is involved in regulating a number of homeostatic pathways, including the
metabolism and storage of macromolecules. Cells that lack a functional copy of VHL
(VHL-deficient) lose control of multiple metabolic pathways, leading to decreased βoxidation of fatty acids, increased synthesis of fatty acids and glycogen, and increased
storage of fatty acids and esterified cholesterol (13,14). The end result is a cell with
clear, lipid-filled cytoplasm.
While VHL inactivation and subsequent lipid accumulation may prove to be an
etiological link between established risk factors of ccRCC and the disease itself, VHL
deficiency plays other, more significant roles in cancer initiation and progression. The
best understood function of VHL is as a master regulator of the hypoxic response, and
key tumour suppressor for many cells in the body (16). In combination with hypoxiainducible factors (HIFs) and prolyl hydroxylase (PHD), VHL ultimately controls the
expression of genes that allow cells to cope with the harmful effects of hypoxia, and
restore cellular oxygenation. HIFs are heterodimeric transcription factors composed of α
(HIF-α) and β (HIF-β) subunits that promote the transcription of genes containing
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hypoxia response elements (HREs). PHD is an enzyme that hydroxylates proline
residues on various proteins, but only in the presence of an essential cofactor – oxygen.
As mentioned previously, VHL is an E3 ubiquitin ligase that specifically recognizes and
binds to proteins with hydroxylated proline residues and targets them for proteasomal
degradation through ubiquitination. HIF-β subunits are not a substrate for hydroxylation
by PHD, and therefore are consistently present under normoxic and hypoxic conditions.
HIF-α subunits on the other hand are hydroxylated by PHD and targeted for degradation
by VHL under normoxic conditions to ensure that hypoxia response genes are not
expressed unnecessarily (17). However when oxygen is absent during periods of
hypoxia, PHD cannot hydroxylate HIF-α residues, allowing them to escape recognition
by VHL, form a functional heterodimer with HIF-β, translocate to the nucleus, and
initiate the hypoxic response (16).
Genes containing HREs include vascular endothelial growth factor (VEGF), plateletderived growth factor (PDGF), transforming growth factor alpha (TGF- α), glucose
transporter-1 (GLUT-1), matrix metalloproteinases (MMPs), carbonic anhydrase IX,
erythropoietin, cyclooxygenase-2, c-MYC, cyclin D1, and many more (18). Induction of
many of these genes through the VHL/HIF pathway is a useful means of minimizing
injury and re-establishing tissue oxygenation during periods of hypoxia that occur
following disruptions in blood supply (19). However, when these genes are aberrantly
expressed under normoxic conditions as a result of VHL inactivation, the resulting cells
are hyperproliferative, invasive, angiogenic and cell death-resistant as a result of their
perceived hypoxia, or pseudohypoxia (Figure 1) (14). It is this pseudohypoxia, as a result
of VHL inactivation, that plays the largest role in the initiation and progression of
ccRCC.
As a tumour suppressor, VHL only loses its function after both genetic copies of the gene
have been lost as a result of deletion, silencing via methylation, or some other form of
mutation (15). In other words, spontaneous ccRCC often only occurs when an already
heterozygous cell loses its functional genetic copy of VHL following a “second hit,”
resulting in complete loss of protein function. Loss of VHL function is common in many
cancers, but it was first discovered to have tumourigenic consequences in a rare
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autosomal-dominant condition known as VHL Disease (20). The majority (80%) of
patients afflicted with VHL disease inherit a mutant copy of VHL from one of their
parents, and following mutation to the second copy begin to develop cysts and tumours of
the kidney (ccRCC), pancreas, retina, and other areas of the central nervous system (16).
It was from studying this rare hereditary disease that the tumour suppressive role of VHL
in ccRCC and other cancers was elucidated (21).
Clearly VHL loss of function is an important step in neoplastic and malignant
transformation. However this, by itself, is neither necessary nor sufficient for the
formation of ccRCC tumours (22,23). Furthermore, there has been no conclusive
evidence which suggests that VHL mutation status – regardless of its overall effect on
VHL function – holds any value as a biomarker or prognostic indicator (16). It is now
generally accepted that classification of ccRCC tumours as VHL-deficient versus VHL
WT is not sufficient. VHL-deficient tumours can be further subdivided according to the
degree to which they express the two major HIF-α isoforms (HIF-1α and HIF-2α). There
are VHL-deficient tumours which aberrantly express increased levels of HIF-1α and HIF2α (H1H2), and those which express increased levels of HIF-2α only (H2) (24). Several
studies have highlighted that HIF-1α and HIF-2α have very different effects on gene
transcription in ccRCC (25), and most suggest that VHL-deficient H2 tumours are more
proliferative and angiogenic than their H1H2 counterparts (26,27).
The increased proliferation of H2 ccRCC cell lines and tumours is in part due to
autocrine growth signaling that occurs through HIF-2α, TGF-α and the epidermal growth
factor receptor (EGFR) that binds TGF-α (26,28,29). Furthermore, the activity of
oncoproteins such as c-MYC and cyclin D1 are upregulated by HIF-2α (24,26), whereas
the activity of pro-apoptotic genes such as BNip3 are upregulated by HIF-1α (26).
Angiogenesis in pseudohypoxic ccRCC cells also appears to be driven by induction of
VEGF through HIF-2α, and loss of HIF-1α may actually exacerbate this process due to a
loss of feedback inhibition that is normally mediated by HIF-1α (26,27). Not only is the
H2 phenotype more aggressive than the H1H2 phenotype, but it may actually be more
common in VHL-deficient ccRCC tumours as a result of a greater likelihood of HIF-1α
undergoing degradation than HIF-2α (18). It has even been suggested that H2 tumours
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are derived from H1H2 tumours and that loss of HIF-1α is a key step in ccRCC tumour
progression (9,30).
With HIF-α transcription factors identified as mediators of ccRCC progression, the
development of therapies is now focused on inhibiting the pathways that the downstream
effectors of HIF-1/2 α (VEGF, TGF-α, etc.) feed into. The development of this targeted
therapy approach has improved PFS of patients with ccRCC and represents a small
victory in cancer treatment (31). However, these therapies are not curative, and are only
effective for a matter of months before the cancer becomes resistant to them.

1.1.2

Past and Present (cc)RCC Therapies

First-line treatment of localized RCC, regardless of histotype, is usually surgery seeing as
it is the only curative therapeutic approach (32). When determining the extent of renal
mass to be excised, a number of factors must be evaluated. The staging of the tumour
according to size and presence/absence of local/distant metastases (TNM staging) is the
first to be evaluated. Patients with T1 tumours (<7 cm, limited to kidney) are often good
candidates for a partial nephrectomy (PN), a procedure in which only the tumour and
immediate surrounding area of the kidney are removed (33). Experienced centers may
even perform this PN laparoscopically instead of opting for traditional open surgery. PN
is the preferred course of treatment where the tumour is affecting a solitary functional
kidney or the patient is in overall poor condition. In these cases, sparing as much
functional tissue as possible is a priority and active surveillance may be preferred to
surgery. Removal of the entire kidney, or radical nephrectomy (RN), is recommended in
cases of locally advanced tumour growth or unfavourable tumour location. RN is often
performed laparoscopically for T2 tumours (7-10 cm, limited to kidney), however open
surgery is recommended for T3 and T4 tumours which involve local and distant
metastases (32).
There are additional, minimally invasive first-line therapies for patients with localized
disease who may not be good surgical candidates. RCC tumours have been shown to
respond to various ablation therapies such as percutaneous radiofrequency ablation,
microwave ablation, laser ablation, cryoablation and high-intensity focused ultrasound
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ablation. The local progression rates for these therapies are often higher than those of
partial and radical nephrectomy, however they are useful for treatment of incidental
lesions in the elderly, multiple bilateral tumours, recurring small renal masses, and
patients at risk of losing all renal function following nephrectomy (32). In general,
treatment of localized RCC with surgery is good, but it is not perfect. The 5-year
survival rate of patients with stage I disease (T1, N0, M0) is >90%. However relapse
occurs within 5 years of surgery for patients with stage II (T2, N0, M0) or III (T3, N0,
M0; T1-3, N1, M0) disease (34). Aggravating this situation is the fact that we have yet to
identify adjuvant therapies that might manage this risk of relapse (35,36). Managing
intermediate/high-risk RCC in its early stages is just as important as targeting stage IV
mRCC, which presents its own set of challenges (36).
When possible, removal of metastases through surgery (metastectomy) can improve
prognosis if all metastatic lesions are completely removed (37). However, systemic
therapy is often required in cases where metastases are unresectable and/or burden of
disease is too great (32). Chemotherapy and radiation therapy have, unfortunately,
proven to be ineffective for treatment of mRCC, regardless of histotype. Poor response
rates – ranging from 0-14% – to a wide range of cytotoxic agents have been welldocumented and are attributed to expression of multi-drug resistance gene 1 and its
protein product P-glycoprotein (8). The molecular mechanisms conferring resistance to
radiation therapy are less well understood, however there have been links drawn to
increased expression of HIF-2α and survivin (38,39). While investigations into these
therapeutic immunities were being made, it was found that immune-based therapies were
a viable treatment option for mRCC (2).
Alongside melanoma, RCC is considered to be one of the most immunogenic of all
human malignancies. This is based on high tumoural infiltration of cytotoxic T-cells and
other immune cells that can recognize tumour-associated antigens, the occurrence of
RCC in patients receiving immunosuppression, and rare observation of spontaneous
metastatic regression (40). Of the wide array of immunotherapies investigated, cytokinebased therapies such as high-dose interleukin-2 (IL-2) and interferon-alpha (IFN-α) have
proven to be most effective and were recommended for treatment of mRCC prior to the
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advent of targeted therapies. Some argue that such therapies are indeed still relevant for
treatment of mRCC given their durable responses in a subset of patients, which is an area
where newer therapies fall short (41,42). However, finding predictive biomarkers that
can identify this subset of patients is a priority given the fact that associated toxicities of
cytokine therapy are generally higher grade when compared to targeted therapies (42).
First-line treatment of low-risk mRCC with IFN-α may also be just as effective as the
currently recommended first-line targeted therapy sunitinib, but at significantly lower
cost it could improve economic efficiency (41). Combination treatments consisting of
cytokine/targeted therapy are also being investigated and present the possibility of
durable responses in a larger proportion of patients (36,41,42).
From increased understanding of the molecular pathways that are active in RCC,
specifically ccRCC, have emerged therapies that hone in on these pathways. These
targeted therapies come in two forms: small molecule inhibitors (SMIs), and monoclonal
antibodies (mAbs). Since 2007, 8 targeted therapies – sorafenib, sunitinib, temsirolimus,
bevacizumab, everolimus, pazopanib, axitinib and tivozanib – have been approved for
mRCC treatment (1,11,12). Of these drugs, only bevacizumab is a mAb and it is targeted
against VEGF. The remaining 7 are SMIs that fall into two classes, receptor tyrosine
kinase (RTK) inhibitors (RTKIs) and mammalian target of rapamycin (mTOR) inhibitors.
The RTKIs that are approved and/or in clinical trials for ccRCC – sunitinib, sorafenib,
pazopanib, axitinib and tivozanib – primarily act on endothelial cell VEGF and PDGF
receptors, inhibiting signal transduction initiated by tumour cell-secreted VEGF and
PDGF (1). The mAb bevacizumab is specific for VEGF and prevents VEGF from
interacting with its receptor on endothelial cells, thus inhibiting signaling between the
tumour and blood vessels in a similar fashion (1). In this way, RTKIs and bevacizumab
target both current metastases – by preventing the initial attraction of blood vessels
(neovascularization) to secondary tumours – and future metastases – by preventing the
growth of new blood vessels towards the primary tumour (angiogenesis) that allow
tumour cells to travel throughout the body (1). While RTKIs can induce necrotic cell
death in larger tumours as a result of decreased microvascular density (MVD), RTKIs
display limited cytotoxicity when administered to ccRCC cells in vitro (43). However,
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some off-target effects of RTKIs acting on tumour cells directly have been documented.
For example, some of sorafenib’s efficacy may stem from off-target inhibition of cyclin
D1, cyclin B1 and survivin (44). Likewise, sunitinib has been observed to enhance the
anti-tumoural immune response by recruiting regulatory T-cells (45). In general though,
RTKIs and bevacizumab target mRCC by preventing vascularization of the primary
tumour and its metastases, with the intention of enhancing cell death, reducing metabolic
output, and preventing future metastases.
Unlike RTKIs, mTOR inhibitors are more direct in their treatment of ccRCC in that they
target a signaling pathway that is overactive in the cancer cells themselves. mTOR can
exist as a member of two functionally distinct complexes, mTOR complex 1 (mTORC1)
and mTOR complex 2 (mTORC2). Both mTORC1 and mTORC2 regulate cell
proliferation, cell survival, nutrient sensing, energy sensing, overall protein translation
and angiogenesis, though their effects on these processes are not synonymous (1,46).
The mTOR inhibitors currently approved for ccRCC – temsirolimus and everolimus –
both prevent the formation of mTORC1, which results in decreased translation of HIF1α, cyclin D1 and c-MYC (1). However as discussed previously, it is thought that HIF2α is responsible for most of the tumourigenic signaling in ccRCC, and its translation is
primarily mediated by mTORC2 (47). Furthermore, inhibition of mTORC1 alone has
been shown to induce a paradoxical increase in the formation of mTORC2. Therefore,
while mTORC1 inhibitors may have some effect on cell proliferation and survival, they
could actually be exacerbating the angiogenic response through increased activity of
mTORC2, increased expression of HIF-2α and subsequent secretion of VEGF (48). For
this reason, SMIs that simultaneously target mTORC1/2 as well as the associated growth
signaling kinases phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt) are
currently in development, though they have yet to reach clinical trials for management of
mRCC (1,48).
While RTKIs, mAbs that target VEGF, and mTOR inhibitors have all shown to improve
PFS and objective response rates (ORR) when compared to cytokine-based therapies,
many have noted that durable, complete responses remain rare. Furthermore, while most
assume that all of the approved targeted agents offer improved OS, improvements in OS
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have only been objectively shown for some of the targeted agents, (1,11,12,31,34). The
adverse events associated with these targeted therapies, especially next generation RTKIs
like pazopanib and tivozanib, are also considered to be less severe than those associated
with cytokine-based therapies (12,42). For these reasons, RTKIs are now the current firstline standard of care for patients with metastatic ccRCC and a favourable risk
categorization (34). However, given the relatively recent approval of these drugs for
treatment of mRCC, there is a significant lack of prognostic information to aid clinicians
in deciding which drugs are most likely to work in which patients, and the order in which
they should be administered (12). In fact, with the exception of bevacizumab + IFN-α,
there is evidence to suggest that combined therapies – especially those combining
multiple targeted therapies – are associated with serious adverse events (11).
Significant investment has been made into developing and refining RTKI and mTOR
inhibitors in order to increase their specificity, thus increasing potency and decreasing the
likelihood of adverse events (12). However, we already know that though RTKIs
developed for ccRCC are anti-angiogenic, they are not cytotoxic in and of themselves
(unless you consider their off-target effects). Likewise, though mTOR inhibitors are
cytotoxic, they are not anti-angiogenic (they may actually be pro-angiogenic). Given the
hazards associated with combined therapy, it seems that currently available treatment
options are not capable of simultaneously targeting cell survival and angiogenesis, which
may prove to be necessary in improving overall survival in a large proportion of patients
(11). In summary, while targeted therapies have shown to be effective, investigation into
new targets that play a role in both survival and angiogenesis is something that should be
considered.

1.1.3

ccRCC Metabolism – The Warburg Effect

VHL inactivation and HIF-α stabilization occur early in the development of ccRCC,
however these events alone do not lead to ccRCC. In fact 20% of VHL-knockout mice
develop renal cysts that never progress to ccRCC (23). Additional events such as
activation of oncogenic signaling pathways, inactivation of DNA repair mechanisms, and
changes in cellular metabolism are required before small renal masses can be considered
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cancerous. It is these additional events that further facilitate tumour progression, and
might be better targets for therapy (14).
The change in metabolism that occurs in ccRCC, and many other cancers, is known as
the “Warburg Effect” and involves a shift from aerobic respiration pathways to anaerobic
respiration pathways, even when oxygen is abundant (49-51). Whereas aerobic
respiration generates ATP through the tricarboxylic acid (TCA) cycle and the electron
transport chain (ETC), anaerobic respiration generates ATP through glycolysis. The
switch to aerobic glycolysis occurs in almost all RCC histotypes as a result of HIF-1α
accumulation. While HIF-1α stabilization is due to VHL inactivation in ccRCC, its
stabilization in other histotypes is due to mutation of key metabolic enzymes that
ultimately result in inhibition of PHD (10,14). Regardless of the mechanism,
accumulation of HIF-1α subsequently results in the upregulation of key enzymes
involved in glycolysis. HIF-1α stabilization ultimately uncouples glycolysis from the
TCA cycle via upregulation of pyruvate dehydrogenase kinase (PDK). PDK inactivates
pyruvate dehydrogenase (PD) through phosphorylation, thus preventing the end product
of glycolysis, pyruvate, from heading towards aerobic metabolic pathways (14,51).
Instead of heading towards the TCA cycle, pyruvate is converted into lactate via lactate
dehydrogenase (LDH) – another HIF-1α target – which allows for the regeneration of
oxidized nicotinamide adenine dinucleotide (NAD+) from its reduced form (NADH)
(14,52). This alongside upregulation of GLUT-1 – yet another HIF-1α target – ensures
that glycolysis substrates are in ample supply (14).
From the perspective of ATP production, shifting metabolites away from oxidative
phosphorylation – ATP produced by the ETC – and towards substrate-level
phosphorylation – ATP produced by glycolysis – is energetically unfavourable when
oxygen is available. This has led cancer biologists to question the selective advantage
that the Warburg Effect provides RCC and other cancers. One selective advantage that
has been suggested is the decreased production of reactive oxygen species (ROS) that
comes with decreased oxidative phosphorylation (53). In addition to uncoupling
glycolysis from the TCA cycle by upregulating PDK, HIF-1α accumulation also leads to
upregulation of the enzyme pyruvate kinase (PK) that facilitates the final step of
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glycolysis – conversion of phosphoenolpyruvate into pyruvate. PK comes in two
isoforms, PKM1 and PKM2, which have variable activities. ccRCC tumours often
express the slower-acting PKM2 isoform as a result of c-MYC-mediated alternative
splicing (54). As a result of this delay at the end of glycolysis, metabolites produced
earlier in the glycolytic pathway accumulate and are available for other processes. One
such process is the pentose phosphate pathway (PPP) which produces nicotinamide
adenine dinucleotide phosphate (NADPH) – a molecule that helps cells cope with
oxidative stress through various mechanisms – and molecules like ribose 5-phosphate and
erythrose 4-phosphate – that are required for the synthesis of proteins and nucleic acids
(53). Therefore despite reducing overall ATP production, aerobic glycolysis ensures that
the enhanced growth of RCC tumours occurs in a cellular environment in which; i)
oxidative stress is regulated and ii) there are sufficient materials for production of
biomass (53).
HIF-1/2α accumulation also appears to suppress ROS production by inhibiting
mitochondrial biogenesis, mitochondrial respiration and overall O2 consumption (55). As
mentioned earlier, ccRCC tumours often express elevated levels of c-MYC. c-MYC can
heterodimerize with MYC-associated factor X (MAX) to form a transcriptional activator
of peroxisome proliferator-activated receptor gamma coactivator 1-beta (PGC-1β) – a
gene that promotes mitochondrial biogenesis (55). On the other hand, MAX can
heterodimerize with MAX-interacting protein 1 (MXI1) to form a transcriptional
repressor of PGC-1β, thus suppressing mitochondrial biogenesis. MXI1 happens to be a
target of HIF-1/2α and is overexpressed in ccRCC (56), which results in greater
formation of MXI1:MAX than c-MYC:MAX, overall repression of mitochondrial
biogenesis, and overall decreased O2 consumption (55). There is also evidence that HIF1α-mediated upregulation of LDH inhibits mitochondrial respiration by competing for the
same pool of NADH that is required for maintenance of the mitochondrial membrane
potential and oxidative phosphorylation (52). Not only is LDH more abundant, but its
cytoplasmic localization and faster kinetics ensure that it is able to outcompete
mitochondrial cytochrome oxidases for the NADH being produced by glycolysis (52).
The end result is lower ETC activity, lower O2 consumption, and lower overall ROS
production.
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As the energetically preferred form of cellular metabolism, oxidative phosphorylation
comes at the cost of increased ROS production. When the earth’s atmosphere changed
from a sulfide-rich environment to an oxygen-rich environment, bacterial and archaeal
species were suddenly faced with a new molecule from which they were obligated to
harness their energy. Each species either slowly acquired this new metabolic phenotype
via advantageous genetic mutations over many generations, or perished. This concept,
known as natural selection, is the driving force behind the evolution of species over time.
However natural selection can apply to cells – malignant and benign – not just species as
Darwin originally postulated (57). Cells are able to sense changes in their environment
and react in many ways, just like organisms. Some of these mechanisms have been
known for decades, some have only just come to light, and even more are still waiting to
be discovered.
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Figure 1. VHL/HIF signalling under normoxic, hypoxic, and pseudohypoxic
conditions in ccRCC.
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1.2 Hydrogen Sulfide: The Third Gasotransmitter
Gasotransmitters are small, gaseous, membrane-permeable molecules that are produced
endogenously and in a dedicated fashion within mammalian cells in order to be perceived
and invoke a response (58). Two gaseous molecules – carbon monoxide (CO) and nitric
oxide (NO) – are widely accepted to fit this definition and their effects within the body
have been recognized since the 1960s and 1980s respectively (59,60). The third and most
recently discovered gasotransmitter is hydrogen sulfide (H2S), though its classification as
a bona fide gasotransmitter is still up for debate (61). While there is no doubt that H2S is
a small, membrane-permeable molecule that is produced in a dedicated fashion in nearly
all mammalian cells, there is some disagreement over whether changing levels of H2S can
be sensed, or whether H2S itself is the sensor (61,62). Regardless of how the semantics
play out, it cannot be denied that H2S production in mammalian cells plays important
roles in normal physiology and pathophysiology (58).
It has long been known that at high enough concentrations H2S is a mitochondrial poison
that inhibits Complex IV of the ETC and eliminates aerobic respiration (63). As a result,
nobody thought that H2S could possibly be playing a meaningful role in humans, despite
the fact that there was knowledge of mammalian enzymes that produce H2S (64). The
first physiological function of H2S identified in mammals was its role as a
neurotransmitter in the brain (65). Soon after, H2S was shown to participate in
synergistic smooth muscle relaxation alongside NO (66). To this day, the functions of
H2S are best described in the context of the central nervous system (67,68) and the
cardiovascular system (69-71), although additional functions have been identified in the
digestive system (72,73), musculo-skeletal system (74), endocrine system (75-77),
excretory system (78-80), respiratory system (81,82) and reproductive system (83). Not
only does endogenous H2S production play a role in the normal functioning of these
systems, but disruption of baseline H2S production has been implicated in diseases such
as hypertension, Alzheimer’s Disease, diabetes mellitus, ulcerative colitis and end-stage
renal disease (58,84,85). Furthermore, the enzymes responsible for endogenous H2S
production are expressed ubiquitously in human cells and H2S is found in the blood at
nanomolar to micromolar concentrations (84).
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1.2.1

H2S Production in the Kidneys: The Transsulfuration
Pathway and Oxygen Sensing

Scientists were able to measure endogenous H2S production in vivo before it was known
to be physiologically relevant. The first documented measurements of tissue-derived H2S
were from rat liver and kidney and were simply used as a way to characterize the relative
activities of the enzymes involved in the desulfhydration of L-cysteine (LC) (64). The
three enzymes that facilitate this process are cystathionine γ-lyase (CSE), cystathionine βsynthase (CBS) and 3-mercaptopyruvate sulfurtransferase (MPST). At the time of these
observations, it was known that the liver and kidneys were the major site for the
desulfhydration of LC, although the ultimate purpose of this process was not entirely
clear (64). We now know that these enzymes are important in the kidney because in
addition to facilitating the desulfhydration of LC, they also convert the toxic metabolite
homocysteine (Hcy) into LC (86,87). Together, the conversion of Hcy into LC, and
subsequent processing of LC into sulfane sulfur (S0), sulfites (SO32-), sulfates (SO42-) and
sulfides (S2-, HS-, H2S) is known as the transsulfuration pathway.
It was previously thought that the production of H2S by CBS, CSE and MPST in the
kidney was simply a byproduct of the transsulfuration pathway, necessary only for the
purposes of chemical stoichiometry. It has recently been shown that H2S derived from
CSE and CBS is involved in regulating baseline hemodynamics and properties of renal
tubules. Notably, renal H2S concentrations were found to correlate with renal blood flow
(RBF), glomerular filtration rate (GFR) and urinary excretion of Na+ and K+ – termed
natriuresis and kaliuresis respectively (88). While increased RBF and GFR are likely due
to the well-known vasodilatory effects of H2S, increased natriuresis and kaliuresis are
attributed to the inhibitory effect that H2S has on the Na+/K+ ATPase (NKA) and the
Na+/K+/2Cl− Co-transporter (NKCC) that maintain Na+ transport across renal epithelial
cells (88). There also appears to be a relationship between baseline H2S production,
production of ROS, and regulation of systemic blood pressure through the reninangiotensin system (RAS) that is regulated by mesangial cells (89,90). Although CBS
and CSE are noticeably lacking from glomerular epithelial cells, H2S produced in nearby
proximal tubule epithelial cells may act on glomerular epithelial cells in a paracrine
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fashion to influence global protein synthesis through AMP-activated protein kinase and
mTORC1 (91-93). Similar paracrine functioning of H2S has been implicated in the
vasodilation of proximal tubule capillaries, which also lack CBS and CSE (91).
One postulated function of H2S within the kidney is oxygen sensing (94). This recently
proposed hypothesis builds on empirical evidence that demonstrates that the relative
proportion of sulfur in its oxidized forms (SOx) and reduced forms (HxS) depends on O2
availability (81). When O2 is available under normoxia, the oxidized forms of sulfur are
favoured. Conversely, when O2 is scarce under hypoxia, the reduced forms of sulfur,
such as H2S, are favoured. This is no doubt an oversimplified model, nonetheless there is
significant evidence demonstrating that oxidation of H2S is an effective cellular
mechanism of sensing decreases in O2 in a wide variety of tissues (62,95). Beltowski
proposes that this acute mechanism may be important in regulating oxygenation to the
renal medulla – an area of the kidney that requires tight regulation of blood flow in order
to achieve the balance between hyperosmolality and O2 supply that is required for the
concentration of urine. Maintenance of this steep concentration gradient in the medulla
requires high expression of NKCC channels and comes at the cost of significant O2
consumption (60% of total renal O2 consumption) (94). To ensure that maintenance of
the gradient does not starve medullary cells of O2, it is thought that high CBS expression
in these cells results in accumulation of H2S under hypoxia, inhibition of NKCC and
NKA to reduce O2 demand, and vasodilation of descending vasa recta to increase O2
supply (93,94).
There is much that remains to be investigated regarding the role that endogenous H2S
production plays in maintaining normal renal function, however it is clear that its
presence cannot simply be described as a byproduct of transsulfuration.

1.2.2

H2S Production, Reactivity and Signalling

Gasotransmitters are by no means traditional signalling molecules. Unlike hormones and
neurotransmitters, gasotransmitters are not suitable for long- or even short-term storage.
There are no dedicated receptors for gasotransmitters, nor is there a need for channels to
facilitate the movement of gasotransmitters across cell membranes due to their
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hydrophobicity. As such, once gasotransmitters are enzymatically produced, they are
immediately able to react with various functional groups in their nearby surroundings.
Given the lack of control that the cell has on these molecules following their synthesis, it
is imperative that their production is tightly regulated at the level of enzyme expression
and activity (96).
H2S is synthesized by three enzymes, two of which are localized primarily to the
cytoplasm (CBS and CSE), the other of which is localized primarily to the mitochondria
(MPST), although CBS and CSE have been observed in the nucleus and MPST in the
cytoplasm (97). CBS is primarily regulated post-translationally through various
mechanisms, although its transcription has been shown to be regulated by numerous
transcription factors, including HIF-1/2α (98,99). CBS contains a redox-sensitive heme
co-factor which can regulate enzyme activity in response to other gasotransmitters as well
as oxidative stress. While oxidative stress activates CBS, presence of NO and/or CO
inhibits CBS (100). CBS can also be allosterically activated by S-adenosylmethionine,
which is a precursor of CBS’s major substrate homocysteine (96). Regulation of MPST
is also primarily achieved through post-translational mechanisms. Various intra- and
inter-molecular disulfide bridges can form between cysteine residues under oxidative
conditions, inactivating the enzyme. The presence of certain reducing substrates may
regulate MPST activity by helping to break these inhibitory disulfide bonds under
conditions of oxidative stress (101). Conversely, little is known regarding posttranslational control of CSE activity, although its transcription may be inhibited by nMYC (98).
Once produced, H2S exists in an equilibrium with its anionic form (HS-) and is also
capable of forming reactive polymerized structures known as polysulfides, the effects of
which may be restricted to the cells in which they are produced (67,96). While some
believe that the effects of H2S may actually be mediated by these other reactive sulfur
species, it is generally accepted that H2S exerts its effects by modifying protein activity
post-translationally by reacting with thiol groups of cysteine residues (102). This
reaction – known as S-sulfhydration – results in the formation of a sulfhydryl group (R-SS-H) that alters protein structure and function. From a chemistry standpoint, S-
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sulfhydration is very similar to the reaction by which NO interacts with cysteine residues
– known as S-nitrosylation – however the biological effects of these two gasotransmittermediated post-translational modifications are very different (96,103). Whereas Snitrosylation often results in the inhibition of target proteins, S-sulfhydration can be both
inhibitory and stimulatory. Often, a protein’s activity depends on whether key cysteine
residues have been S-nitrosylated (inactive) or S-sulfhydrated (active) (96). This can be
said for glyceraldehyde 3-phosphatase (GAPDH), a key regulator of glycolysis. SSulfhydration of GAPDH at Cys150 results in a 700% increase in its glycolytic activity
whereas S-nitrosylation of this same residue inhibits the enzyme’s glycolytic function
(102). Competition between H2S, NO and ROS for cysteine residues is likely a way by
which cells buffer the effects of any one of these gaseous molecules, ensuring that a
response is triggered only when levels of one of these molecules significantly outweighs
the others (61).
In addition to altering the activity of phosphatases like GAPDH, H2S also affects the
activity of kinases, ion channels and transcription factors that are involved in regulating
cell survival, cell proliferation, membrane polarization, angiogenesis and inflammation
(104). S-sulfhydration of ATP-dependent K+ (KATP) channels is a stimulant of
vasodilation in the cardiovascular system that may be more potent than NO-mediated
vasodilation (105). H2S has also been shown to promote the anti-apoptotic signaling
cascade initiated by tumour necrosis factor alpha (TNF-α) through S-sulfhydration of the
p65 subunit of the transcription factor nuclear factor kappa B (NF-κB) (106). Finally,
H2S can activate various kinases that promote proliferation and angiogenesis – such as
Akt, protein kinase C (PKC), mitogen-activated protein kinase p38 (p38) and
extracellular signal-related protein kinase (ERK 1/2) – although S-sulfhydration of
kinases is rarely documented in the literature (104).

1.2.3

H2S: Vasodilator and Angiogenic Factor

The synergistic effects of H2S and NO in the cardiovascular system have been known for
quite some time (66). As previously mentioned, both of these gasotransmitters are potent
vasodilators, and their effects may be mutually dependent on one another. Recent work
has demonstrated that H2S and NO are also mutually-dependent stimulants of
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angiogenesis (107). Both vasodilation and angiogenesis are important physiological
responses that occur in response to disruption of normal blood supply following various
ischemic injuries. Whereas vasodilation involves increasing blood flow via relaxation of
smooth muscle cells that surround blood vessels, angiogenesis increases blood flow via
the growth and recruitment of new vascular networks, which requires the proliferation
and migration of endothelial cells. At first glance these responses appear to be quite
distinct, however closer inspection reveals that H2S and NO coordinate these responses
using the same pathway (107).
Activation of protein kinase G (PKG) is the junction at which gasotransmitter production
and the induction of angiogenesis/vasodilation meet. In order for PKG to phosphorylate
its target proteins, the co-factor cyclic guanosine monophosphate (cGMP) is required.
Production of cGMP is accomplished via guanylyl cyclase (GC), and degradation of
cGMP is accomplished via phosphodiesterase type 5 (PDE5). cGMP levels rise in the
presence of NO and H2S because NO activates GC – increasing cGMP production – and
H2S tonically inhibits PDE5 – decreasing cGMP degradation (107). Knock-out/inhibition
of either one of the major endothelial enzymes responsible for NO and H2S synthesis –
endothelial nitric oxide synthase (eNOS) and CSE respectively – results in complete loss
of the angiogenic response to VEGF and the vasodilatory response to cholinergic
stimulation (107,108). This suggests that baseline production of H2S and NO in
endothelial cells is a necessary component of these cardiovascular responses.
Focusing on the angiogenic response, several groups have shown that exogenous H2S can
induce endothelial cell proliferation, tube formation and migration via PKG-mediated
phosphorylation of ERK 1/2 and p38 (107-109). What is more interesting, is that VEGFmediated angiogenesis appears to require endogenous H2S production, suggesting that
VEGF exerts its angiogenic effects through H2S (108). In addition to inhibiting cGMP
degradation by PDE5, it is thought that increasing levels of H2S may increase cGMP via
Akt-mediated activation of eNOS (107). This is based on evidence that Akt is activated
in response to exogenous/endogenous H2S production, albeit the mechanism is not
currently known (107-109). The exact mechanisms that link VEGF, H2S and NO are still
being worked out, however a relationship surely exists.
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1.2.4

H2S: Antioxidative and Cytoprotective

When referring to oxidative damage, one is referring to the damage that cells incur as a
result of generating ATP through oxidative phosphorylation. As the ultimate acceptor of
electrons utilized in the ETC, O2 must be present in abundance to ensure that electrons
are quenched in pairs and not in isolation. When molecules with stable electronic
configuration happen to accept a single electron, the result is an unstable free radical that
can disrupt cellular function by inappropriately reacting with and damaging DNA,
proteins and lipids. Free radicals that are most commonly formed in cells usually contain
oxygen – referred to as ROS – or nitrogen – referred to as reactive nitrogen species
(RNS). While the presence of moderate levels of ROS/RNS is normal and even
necessary for appropriate cell signaling, excessive production of ROS/RNS has been
implicated in several diseases, many of them age-associated. While mitochondrial
dysfunction and other kinds of cell stress result in oxidative damage as a result of
increased ROS/RNS production, oxidative damage can also occur as a result of decreased
degradation of ROS/RNS by antioxidative mechanisms (110).
Several studies have shown that exogenous administration and/or endogenous production
of H2S can attenuate injury and cellular senescence caused by oxidative stress (111-115).
It was originally believed that H2S mediates these antioxidative effects by reacting
directly with ROS and RNS. However, due to the relatively low abundance of H2S
compared to other cellular reductants like glutathione, as well as the low rate constants
for H2S-mediated oxidation, it seems likely that this is not the case (111). To explain the
antioxidative properties of H2S, it has been postulated that they could simply be the result
of reversible Complex IV inhibition, decreasing metabolic rate and overall ROS
production (116). H2S has also been shown to react with electrophiles that are generated
during oxidative damage and lead cells down cell death/senescence pathways. In this
way H2S blunts the cell’s response to oxidative stress, promoting damage recovery as
opposed to cell death (117). Along the same line, H2S can abrogate apoptosis by
counteracting declines in mitochondrial membrane potential and preventing caspase
activation (112).
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Alternatively, exogenous H2S can induce the antioxidant response through regulation of
the master transcription factor NF-E2 p45-related factor 2 (Nrf2). Under normal REDOX
conditions, Nrf2 is degraded by kelch-like ECH-associated protein-associated protein-1
(Keap1), however under oxidative stress H2S inactivates Keap1 through S-sulfhydration,
allowing Nrf2 to accumulate and induce expression of antioxidative proteins (118).
Interestingly, CBS and CSE are amongst the antioxidative proteins that are induced by
Nrf-2, creating a positive feedback loop in which H2S production plays a central role
(118). This positive feedback loop could explain how H2S can pre-condition cells to
various forms of injury that involve oxidative stress (119). Regardless of the mechanism,
H2S is clearly playing an important role in responding to oxidative stress.

1.2.5

H2S: Metabolic Substrate and Regulator

Given its toxic reputation, it is rather hard to believe that H2S could be contributing to
mammalian cellular metabolism in any meaningful way. The existence of prokaryotes
that oxidize sulfides for energy production has been known for decades. However, these
anaerobic organisms – which usually inhabit sulfide-rich environments like the deep
ocean or volcanic springs similar to primordial earth– cannot rely on oxidative
phosphorylation for ATP production like humans and other aerobic organisms do.
However, when one considers the endosymbiotic relationship that links eukaryotic
mitochondria with ancient sulfide-oxidizing prokaryotes, perhaps it is not surprising that
eukaryotes retained a sulfide oxidation pathway (120). Conversion of H2S into persulfide
(S22-), sulfite (SO32-), thiosulfate (S2O32-) and sulfate (SO42-) occurs under aerobic
conditions and is important in ensuring that H2S does not inhibit the heme co-factors of
Complex IV of the ETC, halting oxidative phosphorylation and ATP synthesis (121). In
fact, given the high flux of sulfur into H2S we know that most of the H2S being produced
under normoxic conditions is removed via mitochondrial oxidation in order to account for
the relatively low concentration of H2S in mammalian tissues (111). This is especially
true for epithelial cells of the kidney and colon which are exposed to high levels of H2S
produced by the transsulfuration pathway and H2S-producing bacteria respectively (122).
While these physiological adaptations are impressive in their own right, what is truly
impressive is that these, and other cells of the body, are capable of funneling the electrons

22

liberated by sulfide oxidation into the ETC to contribute to ATP production. This makes
H2S the first inorganic substrate for oxidative phosphorylation identified in mammalian
cells (121).
The first step of sulfide oxidation in mammalian cells is the transfer of electrons from
H2S to coenzyme quinone (Q), which is catalyzed by sulfide quinone reductase (SQR)
(122). When compared to the canonical players involved in the ETC, H2S is analogous to
NADH in that they are both the primary donors of electrons, and SQR is analogous to
Complex I in that they both feed into coenzyme Q (120). Following loss of its electrons,
H2S is processed by a sulfide-oxidizing unit (SOU) consisting of a dioxygenase and
sulfurtransferase through a mechanism that requires one molecule of O2. In this way,
oxidation of 1 mole of H2S requires 1.5 moles of O2 (1 mole for SOU and 0.5 moles for
Complex IV), which is considerably more than the 0.5 moles of O2 required for oxidation
of NADH. Therefore, oxidation of sulfide in eukaryotes is an oxygen-dependent process,
which is why H2S levels rise under hypoxia (62). The differences in stoichiometry also
highlight that oxidation of H2S is energetically less favourable than oxidation of NADH
in that it only supplies half of the electrons. Furthermore, catabolism of L-cysteine into
pyruvate would yield ten times the number of electrons available for oxidative
phosphorylation when compared to catabolism of L-cysteine into H2S. This prompts the
question “Why would eukaryotic cells saturate the activity of coenzyme Q with H2S/SQR
when electron transport through NADH/Complex I is much more efficient?” (120).
The reasons for this are three-fold, and together they emphasize the role of H2S as an
‘emergency substrate.’ First and foremost, H2S is membrane-permeable so gaining
access to the mitochondria does not require additional energy expenditure for transport
and also occurs rapidly. Second, production of H2S from L-cysteine does not require
energy investment as is the case for metabolism of carbon sources which requires initial
activation before reducing agents like NADH can be produced. Finally, the SOU has a
high affinity for H2S when present at physiological concentrations which ensures that
nearly all of it is used for production of ATP (120). The role of H2S as an emergency
metabolic substrate following various stresses has been demonstrated in smooth muscle
cells and hepatocytes (123,124).
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Tackling this issue from another angle, it has also been suggested that by competing with
electron donors from carbon-based metabolism, H2S may play a role in fine-tuning
oxygen consumption. It has been shown that moderate levels of H2S (100 nM – 10 μM)
can stimulate oxygen consumption in the presence of various carbon-based metabolic
substrates in vitro, whereas higher levels of H2S (>10 μM) overwhelm the SOU, inhibit
Complex IV and decrease oxygen consumption (125). Increasing oxygen consumption
through the SOU can be useful in reducing oxidative stress associated with oxidative
phosphorylation and may be a key link between cellular REDOX potential and cellular
metabolism. With increased aerobic respiration comes increased risk of oxidative stress,
however moderate H2S production may allow cells to achieve the same metabolic output
with less oxidative damage. Production of H2S also increases glycolysis through Ssulfhydration of GAPDH, as previously mentioned.
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Figure 2. Cellular H2S metabolism and signalling.
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1.3 H2S and Cancer
Given its many properties, the therapeutic potential of H2S has been investigated in many
disease states, including cancer. In many of these disease states endogenous H2S
production seems to have been suppressed or lost, in which case exogenous
administration of H2S has been investigated as a treatment option. In these cases,
determining the proper dose, method of administration, and even rate of release through
the use of slow-release H2S-donour molecules are major challenges due to the small
range of concentrations at which H2S is effective before it becomes toxic (85). These
same issues have led to conflicting results on the role that H2S plays in various cancers.

1.3.1

Exogenous H2S as a Cancer Treatment?

It has been shown that exogenous H2S treatment can restrict gastric cancer growth and
survival, although the dose used in vitro was not shown to be non-toxic to non-malignant
cells and the mechanism of action in vivo was not identified (126). Exogenous H2S
treatment has also been shown to target the growth and survival of oral cancer, breast
cancer and hepatoma cell lines over non-malignant cell lines of similar origin. However
the pro-apoptotic effects of H2S in these instances are reliant on the presence/absence of
certain proteins (127,128). If one believes that proliferating cancer cells are affected by
natural selection in the same way that all organisms are, then one would expect that
endogenous H2S production would be down-regulated if H2S is indeed anti-tumoural.
However, decreased expression of H2S-producing enzymes – and decreased endogenous
H2S production – has only been shown in aggressive prostate cancer cell lines (129). In
fact, the opposite seems to be true when evaluating endogenous H2S production in most
cancer cell lines, and inhibition of this enhanced H2S production targets cell growth,
survival, metabolic output, migration, angiogenic potential and therapy-resistance.

1.3.2

Role of Endogenous H2S Production in Cancer

Much attention has been paid to the role that endogenous H2S production plays in the
progression of colon cancer, given that the colon is rich in bacterial H2S that is
continuously being oxidized in the mitochondria of colonocytes (122). It was first shown
that exogenous H2S treatment could enhance cell cycle entry in several colon cancer cell
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lines by increasing Akt activation and decreasing expression of the cell cycle inhibitor
p21 (130). More recently, it was shown that several malignant traits of colon cancer were
due to enhanced expression of CBS in human tumours and malignant cell lines when
compared to non-malignant samples (131). In addition to facilitating proliferation in
vitro, increased endogenous H2S production was contributing to cell migration and cell
bioenergetics. When cell lines were xenografted in vivo, silencing/inhibition of CBS
could attenuate tumour growth and blood supply (131). CSE has also been implicated in
facilitating colon cancer growth, migration and vascularization, and its expression
appears to be transcriptionally up-regulated in cell lines characterized by aberrant Wnt
signalling (132).
CBS was also found to be upregulated in human epithelial ovarian cancer cell lines and
tissue samples when compared to normal epithelial cells, and inhibition/knock-down of
CBS restricted cell growth, cell viability and cellular metabolism in vitro. When
xenoplanted into mice, silencing of CBS was also able to reduce xenograft
neovascularization and sensitized tumours to platinum-based chemotherapy which cells
had previously been resistant towards (133). Whether H2S itself was able to protect
against the oxidative stress induced by the chemotherapy was not investigated, however it
has been shown that induction of CBS/CSE and elevated H2S production under hypoxia
contributes to hypoxia-induced radiation therapy resistance in hepatoma cells (134). It
has also been suggested that bystander effects – tumour cell death surrounding the
irradiated area of the tumour – in hepatocellular carcinoma may also be the result of
decreased endogenous H2S synthesis (135). Together, these studies suggest that
inhibition of endogenous H2S production could prove to be an effective adjuvant therapy
in tumours such as ccRCC that are hypoxic and/or resistant to chemotherapy/radiation
therapy.
An important aspect of natural selection is the presence of a selective pressure. From the
point of view of cancer cells, naturally occurring selective pressures include hypoxia,
nutrient deprivation, and oxidative stress. However, by targeting cancer cells with
specific therapies we can introduce additional selective pressures that cancer cells may or
may not adapt to. Only a subset of cells will survive these pressures, proliferate and lead
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to changes in the cellular make-up and behaviour of tumours over time, a process referred
to as tumour progression (136). Recent studies have shown that breast, liver and colon
cancer cell lines are able to recover from cell damage induced by nutrient deprivation,
hypoxia, oxidative stress and chemotherapeutics through a mechanism involving H2S
(137,138). Essentially, damage-recovered cells exhibit increased endogenous H2S
production which upregulates nicotinamide phosphoribosyltransferase (Nampt), an
enzyme involved in salvaging NAD+ and driving aerobic glycolysis. Damage-recovered
cells therefore display reduced mitochondrial bioenergetics, increased aerobic glycolysis,
increased resistance to oxidative stress, and increased proliferation as a result of this H2SNampt pathway (138). This same pathway has also been shown to be associated with the
stem-like phenotype of cancer cells that survive such damage (139).

1.3.3

Role of H2S in kidney cancer

Renal malignancies, specifically ccRCC tumours, have been described as metabolic
diseases that display dysfunctional oxygen-, nutrient-, and energy-sensing pathways (9).
Functional loss of the tumour suppressor VHL is responsible for this dysfunction in that it
results in the accumulation of HIF-1/2α, rendering ccRCC tumours pseudohypoxic (14).
This pseudohypoxia results in an overall shift in metabolism that results in the activation
of aerobic glycolysis, suppression of mitochondrial bioenergetics, and flux of glycolytic
metabolites towards production of reducing agents and biomass – otherwise known as the
Warburg Effect (53). Finally, pseudohypoxic ccRCC tumours are highly angiogenic due
to their high secretion of VEGF, which increases their access to vasculature and the rest
of the body (18).
H2S is an endogenously-produced molecule that functions as an oxygen sensor (62),
angiogenic factor (108), metabolic substrate (122), and cytoprotectant (111). In renal
epithelial cells, H2S is produced in abundance by enzymes that are involved in the
detoxification of homocysteine (64) and this excessive H2S is readily oxidized by
mitochondria under normoxia, contributing to ATP production (122). In the context of
other cancers, it is known that elevated levels of H2S can enhance ATP production and
reduce oxidative stress via mitochondrial oxidation (131,133) or enhanced aerobic
glycolysis (137,138). Finally, endogenous H2S production appears to confer resistance to
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natural pressures felt by cancer cells as well as clinically-administered pressures like
chemotherapy and radiation therapy (134,139).
Taken together, there is considerable evidence to suggest that endogenous H2S
production plays an important role in the progression of kidney cancer, and inhibiting its
production may be a legitimate course of treatment. Specifically, pseudohypoxic ccRCC
tumours may produce particularly high levels of H2S as a result of decreased removal of
H2S via oxidation and increased expression of CBS via HIF-1/2α (99).
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1.4 Hypothesis and Objectives
1.4.1

Hypothesis

It is hypothesized that endogenous production of H2S is upregulated in VHL-deficient
ccRCC cell lines and tumours, and contributes to their survival, growth and angiogenic
potential.

1.4.2

Objective I: Is Endogenous H2S Production Enhanced in
VHL-deficient ccRCC Cell Lines?

Our first objective was to determine whether endogenous production of H2S is enhanced
in VHL-deficient ccRCC cell lines. To investigate this, five cell lines were used. The
non-malignant, human, renal epithelial cell line HK-2 served as the control for four
different ccRCC cell lines: the VHL WT ccRCC cell line Caki-1, two VHL-deficient
ccRCC cell lines 769-P and 786-O, and a 786-O cell line with VHL function restored
using an exogenous lentiviral vector containing a single wild-type allele of the gene (786O VHL+).
As a result of its gaseous nature, quantification of cellular H2S production has proven
difficult and has been a significant hurdle in this field of research. Recently published
articles documenting endogenous H2S production often use the Methylene Blue Assay
which has been practiced since the 1970s but is known to produce false-positive results
by reacting non-specifically with thiols. To avoid such false positive results, we used a
cell-permeable, H2S-specific, fluorescent probe in combination with live-cell imaging to
track endogenous H2S production in our cell cultures in real-time. Cells in the
presence/absence of the probe were imaged at the beginning of experiments as a control
to demonstrate that differences in fluorescent signal were the result of differences in H2S
production, and not differences in background fluorescence. Use of this probe was
impractical in the 786-O VHL+ cell line due to high background fluorescence, and so the
Methylene Blue Assay was used instead in its stead, with heat-killed cells serving as a
control against false-positive results.
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Since the probe only quantifies net H2S production, it alone cannot distinguish between
cell cultures that have a high concentration of H2S due to enhanced production, and cell
cultures that have a high concentration of H2S due to dysfunctional clearance. To more
adequately address whether VHL-deficient ccRCC cell lines display enhanced production
of H2S, western blot analysis of baseline CBS, CSE and MPST expression was
performed. Hypoxic induction of CBS/CSE/MPST expression was also investigated
using western blot analysis to try and establish links between expression of H2Sproducing enzymes, VHL functional status, and HIF-1/2α expression.

1.4.3

Objective II: Does Endogenous H2S Production Contribute to
the Proliferation, Metabolism and Survival of ccRCC Cell
Lines?

Our second objective was to determine whether endogenous production of H2S
contributes to the proliferation, metabolism and survival of ccRCC cell lines. In order to
determine whether endogenous H2S production can be inhibited in our cell lines we
treated them with the validated CBS/CSE inhibitors hydroxylamine (HA) and propargyl
glycine (PAG) (140) and monitored changes in H2S production using the fluorescent
probe described in Objective I. Treating cells with the substrate for endogenous H2S
production (LC) allowed us to evaluate whether endogenous H2S production can be
stimulated above baseline levels, or whether it is at capacity. Combination treatment of
cells with HA and LC will allow us to determine if we can partially rescue H2S
production with LC when the inhibitor is present. Cells were left untreated as a control,
seeing as HA, PAG and LC were all dissolved in phosphate-buffered saline (PBS).
Using these treatments under both normoxic (21% O2) and hypoxic (1% O2) growth
conditions, we evaluated how changing endogenous production of H2S influenced cell
growth, cell survival, and cell metabolism in vitro. Changes in cell growth were
quantified by measuring changes in confluency over time. Cell viability was quantified
via flow cytometry identification of the apoptotic and necrotic markers Annexin-V and 7AAD, respectively. Finally, cell metabolism was quantified using a combination of the
XTT Assay – which quantitates electron turnover by spectrophotometric changes – and
an ATP quantitation kit – which measures cellular ATP concentration using a luciferin-
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luciferase system. The role that VHL mutation status plays in conferring
resistance/susceptibility to such treatments was further investigated here.

1.4.4

Objective III: Does Endogenous H2S Production Contribute
to Neovascularization of ccRCC Xenografts?

Our third objective was to determine whether endogenous production of H2S contributes
to the neovascularization of ccRCC xenografts. In order to investigate this, ccRCC cell
lines were xenografted into the chorioallantoic membranes (CAMs) of developing
chicken embryos. This immune-deficient xenograft model is ideal for studying the
neovascularization of human tumours in real-time (141), and has also been used to study
the effects of H2S on angiogenesis (108). Treatments were administered systemically to
determine whether changes in endogenous H2S production can influence the recruitment
of blood vessels to ccRCC tumours. PBS was injected intravascularly as a control. The
effect of treatments on tumour size was also investigated, as well as the efficacy of
treatments in relation to VHL mutation status.

1.4.5

Objective IV: Is Endogenous H2S Production Enhanced in
human RCC tumours?

Our fourth and final objective was to determine whether expression of the H2S-producing
enzymes CBS and CSE is upregulated in human RCC tumours. In order to investigate
this, immunohistochemical staining of CBS and CSE was performed on samples derived
from 49 patients with renal masses. Tissue was also harvested from non-neoplastic areas
of the affected kidney to serve as an internal control. Expression of each protein in
ccRCC tissue was pathologically scored and compared to expression in normal renal
tissue from the same patient, as well as expression in non-malignant and non-ccRCC
renal masses. Correlations to Fuhrman grade – a pathological indicator of disease
severity – and tumour size were also performed.
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2. Materials and Methods
2.1 Cell Culture
All cells were cultured under normal growth conditions (37 °C, 5% CO2, 21% O2) in
growth media (Gibco®, Burlington, ON) supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin. Subculturing of cells was performed weekly with use of
0.05% trypsin EDTA (Gibco®). The human renal epithelial cell line HK-2 was
generously donated by Dr. Lakshman Gunaratnam (Western University, London, ON)
and cultured in Keratinocyte Serum Free Medium supplemented with human recombinant
Epidermal Growth Factor 1-53 and Bovine Pituitary Extract. The VHL WT ccRCC cell
line Caki-1 was generously donated by Dr. Alison Allan (Western University, London,
ON) and cultured in McCoy’s 5A growth medium. The VHL-deficient ccRCC cell lines
769-P and 786-O were also donated by Dr. L. Gunaratnam and cultured in Dulbecco’s
Modified Eagle Medium. The ccRCC 786-O VHL+ cell line was generously donated by
Dr. James Brugarolas (UT Southwestern, Dallas, TX) and grown in Dulbecco’s Modified
Eagle Medium.

2.2 Treatments
Inhibitors of endogenous H2S synthesis (HA and PAG) and the substrate for endogenous
H2S production (LC), were prepared as 100 mM stock solutions in PBS. Effective doses
ranged from 0.5 mM to 5 mM, depending on the assay, and were used to treat cells
seeded in 96-well, 24-well, 12-well or 6-well plates. Cells were treated for 6-48 hours in
either normoxic growth conditions (37 °C, 5% CO2, 21% O2) or hypoxic growth
conditions (37 °C, 5% CO2, 1% O2) using a HypOxystation® H85 hypoxia chamber
(HYPO2XYGEN, Frederick, MD).
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2.3 Measurement of Endogenous H2S Production
2.3.1

Live Cell Imaging with Fluorescent Probe

A cell-permeable, H2S-specific, fluorescent probe was used in combination with live-cell
imaging to track endogenous H2S production in our cell cultures in real-time. The H2Sspecific probe was generously donated by Dr. Michael Pluth (University of Oregon,
Eugene, OR) and is the second-generation product of probes previously developed in the
Pluth lab. The probe is an azide-functionalized fluorophore that reacts specifically with
H2S to produce a green fluorescent signal (142). The live-cell imaging platform used
here was the IncuCyte ZOOM (Essen BioScience, Ann Arbour, MI) and its use was
graciously afforded by Dr. Anthony Jevnikar (Western University, London, ON). Cells
were seeded into 96-well plates (2 x 104 cells per well) and allowed to adhere overnight.
Treatments and H2S-specific probe were added to wells simultaneously and green
channel fluorescent images of each well were captured every 30 minutes for 15 hours (4X
objective, 440 nm excitation/520 nm emission). Using IncuCyte internal software,
thresholding was performed on wells in which no H2S-specific probe had been added in
order to eliminate background cellular fluorescence. The total number of cells
fluorescing above the established threshold was quantified, yielding a Total Probe Count.
IncuCyte internal software was also able to quantify percentage cell confluency after
additional thresholding, and this was used to normalize the Total Probe Count.

2.3.2

Methylene Blue Assay

Cells were seeded into 6-well plates and allowed to reach 90% confluency. Growth
media was aspirated and cells were washed twice with PBS before the addition of 50 μL
of lysis buffer. Immediately, a solution of zinc acetate (12% NaOH) was added to each
sample to ‘capture’ H2S released by lysis. Subsequent reaction with 20 mM N,Ndimethyl-p-phenylenediamine in 7.2 M HCl and 30 mM FeCl3 in 1.2 M HCl allowed for
a colour change to occur over 10 minutes which was spectrophotometrically quantified at
670 nm. Standard H2S solutions were prepared by dissolving Na2S in lysis buffer and
were processed in parallel. Heat-killed cell pellets were also processed in parallel to
serve as a negative control.
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2.4 Protein Expression Analysis
2.4.1

Protein Isolation

Cells were plated into 60 mm dishes and allowed to reach 90-100% confluency. Cells
were either kept in normoxia or exposed to hypoxia for 6-24 hours. Following treatment,
media was aspirated, cells were washed twice with PBS before being lysed on ice for 15
minutes in RIPA buffer. Lysates were collected and centrifuged at 4 °C and 10,000 x g
for 10 minutes before being aliquoted and stored at -80 °C.

2.4.2

SDS-PAGE and Western Blotting

Forty-fifty micrograms of each sample was run on 10-12%, Tris-glycine, SDSpolyacrylamide gels under thiol-reducing conditions at 60-120 V and transferred to
PVDF membranes for 45 minutes at 80V. Membranes were blocked in TBS (5% BSA)
and incubated overnight at 4°C with primary antibody (mouse-anti-human CBS (B-4):
Santa Cruz Biotechnology Inc., sc-133154; rabbit-anti-human CTH (CSE): Sigma
Aldrich, SAB2100501; mouse-anti-human MPST (D-8): Santa Cruz Biotechnology Inc.,
sc-374326; mouse-anti-human β-actin: Sigma Aldrich, A5441). Membranes were
washed in TBS (1% Tween-20) for 3 x 10 minutes, incubated with HRP-conjugated
secondary antibody (goat-anti-mouse IgG HRP conjugate: Life Technologies™, G21040; goat-anti-rabbit IgG-HRP-conjugate: Jackson Immunoresearch Laboratories Inc.,
111-035-003) for 1 hour at room temperature and washed for 3 x 10 minutes.
Chemiluminescence was induced using Luminata™ Crescendo Western HRP Substrate
(EMD Millipore, WBLUR0100A).

2.4.3

Imaging and Analysis

The majority of blots were imaged using the C-DiGit® Blot Scanner (LI-COR) and
subsequently analyzed using Image Studio Lite version 4.0. Due to equipment
malfunction, some blots were imaged using the FluorChem™ M System (ProteinSimple,
Toronto, ON) and band density was determined using a combination of internal software
(for most blots) and ImageJ Software (for blots with low signal).
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2.5 Cell Proliferation Assay
Cells were seeded into 96-well plates (1 x 104 cells per well) and allowed to adhere
overnight, resulting in roughly 50% confluency at the time of treatment. Treatments
were added to wells and images (4X magnification) of each well were captured every 30
minutes for 12 hours using the IncuCyte ZOOM live-cell imaging platform (Essen
BioScience, Ann Arbour, MI). Using IncuCyte internal software, thresholding was
performed on wells in which cells received no treatment in order to optimize the
quantitation of cell confluency. The percentage change in confluency for each individual
well was then calculated.

2.6 Cell Viability Assay
Cells were seeded into 12-well plates and allowed to reach 70-90% confluency.
Treatments were applied and cells were then placed in hypoxic or normoxic growth
conditions for 48 hours. Following treatment, cells were trypsinized and washed with
PBS in preparation for flow cytometry. Cells were stained with the necrosis marker 7AAD (Biolegend®, 420404) and the apoptosis marker phycoerythrin-conjugated
Annexin-V (Biolegend®, 640908) and analyzed using the Cytomics FC500 flow
cytometer (Beckman Coulter, Mississauga, ON). Heat-killed samples singly stained for
each marker and doubly stained for both markers served as positive controls for
compensation analysis. Cells identified as viable were those negative for both Annexin-V
and 7-AAD, as compared to the gated normoxic control samples.

2.7 XTT Cytotoxicity Assay
Pre-assay optimization was performed according to manufacturer protocol (ATCC, 301011K) which allowed for identification of ideal seeding density and ideal reagent
incubation time. In 96-well plates, 786-O, 769-P and 786-O VHL+ cells were plated at 1
x 104 cells/mL, whereas Caki-1 and HK-2 cells were plated at 5 x 104 cells/mL.
Following plating, cells were allowed to adhere overnight before addition of treatment
and growth under either normoxia or hypoxia. Cells were treated for 44 hours before
addition of XTT Reagent to growth media for the remainder of the 48 hour incubation.
Plates were read by a spectrophotometer at 660 nm, for measurement of non-specific
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absorbance, and again at 475 nm for measurement of metabolic activity. Wells were also
blanked against growth media without cells or drug added. Data was then normalized to
the normoxic control after converting all final readings to positive values.

2.8 ATP Quantitation Assay
Cells were seeded into 24-well plates (3 x 105 cells per well) and allowed to reach 90%
confluency. Treatments were applied and cells were then placed in normoxic or hypoxic
growth conditions for 6 hours. Growth media was aspirated, cells were washed twice
with PBS and boiling ddH2O was used to lyse cells. Cell lysate was transferred to
Eppendorf tubes and centrifuged at 4 °C and 10,000 x g for 10 minutes. The
concentration of ATP in each sample was then quantified using Molecular Probes’ ATP
Determination Kit (Invitrogen, A22066) which employs a luciferin/luciferase
bioluminescence system. Samples were quantified relative to ATP standard solutions
using the luminometer function on the Synergy H4 Hybrid Multi-Mode Microplate
Reader (Biotek Instruments, Winooski, VT), use of which was generously afforded by
Dr. John McCormick (Western University, London, ON). Luminometer readouts were
blanked and converted to ATP concentrations using the curve generated by ATP
standards. ATP concentrations were normalized to protein concentrations for each
sample after protein concentration was quantified using a Bradford protein assay (BioRad, 500-0006) and BSA standards.

2.9 Avian Xenograft Vascularization Model
2.9.1

Lentiviral Infection

Four RCC cell lines (Caki-1, 769-P, 786-O, and 786-O VHL+) were seeded and grown to
50-60% confluency. Cells were inoculated with ZsGreen lentiviral vector containing a
gene for extreme green fluorescent protein (EGFP) and a puromycin resistance gene for
pooled clone selection. Two days following infection, EGFP-expressing cells were
selected for using 1-2 μg/mL of puromycin, depending on the cell line. Puromycin was
removed from growth medium following 2 weeks of sub-culturing.
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2.9.2

Avian Chorioallantoic Membrane Xenografting

Fertilized chicken eggs were incubated at 37°C in humidified, non-sterile conditions for
three days before being cracked and deposited into individual plastic trays. Embryos
were placed back in the incubator and were ready for introduction of cancer cells after
another six days of incubation. On day 9 post-fertilization (pf), a filter paper disc 7 mm
in diameter was placed onto the CAM near large oxygenated blood vessels and
subsequently ripped off to remove the upper-most layers of the CAM. Ten microliters of
a 1:1 suspension of EGFP-expressing cancer cells in BD Matrigel™ were then implanted
on top of this exposed area, and tumours were given two days to establish themselves
within the tissue.

2.9.3

Xenograft Treatment and Processing

At 2 days post-implantation, tumours that had successfully begun recruiting blood vessels
were randomly sorted into four groups. Intravascular injections of 50 µL of either: i) 20
mM HA, ii) 10 mM LC, iii) 20 mM HA + 10 mM LC or iv) PBS vehicle control were
administered daily on days 11 pf through 14 pf. On day 15 pf, embryos were
intravascularly injected with 75 μL of 0.5 mg/mL rhodamine-labelled lens culinaris
agglutinin (rhodamine-LCA; Vector Laboratories, RL-1042) to fluorescently label
vasculature for subsequent analysis prior to harvesting tumours from the CAM. As a
control, 4 PBS-treated tumours were harvested and analyzed without rhodamine-LCA
injection. Tumours were washed in PBS then fixed in 10% neutral buffered formalin
containing 30% sucrose for a minimum of 1 week. Tumours were then embedded in
Optimal Cutting Temperature (OCT) compound and stored at -80°C until sectioning.
Using a CM30505 Cryostat (Leica, Concord, ON), ten 10 μm sections were obtained
from various depths of each tumour, with the plane of sectioning running parallel to the
surface of the once-surrounding CAM.

2.9.4

Quantification of Tumour Size

Fluorescence stereoscope images of tumours were obtained at 20X magnification using
the AX10 Zoom V.16 stereoscope (Zeiss, Toronto, ON) before tumours were harvested
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from the CAM. The cross-sectional area of stereoscope tumour images was measured
using the hand trace tool in ImageJ Software.

2.9.5

Quantitation of Vascularization

Sectioning (Carl Postenka) and imaging/quantitation (Eric Sonke) of tumours were
performed by separate individuals and both were performed in a blinded fashion.
Sections were imaged using the Fluoview FV1200 confocal laser scanning microscope
(Olympus, Toronto, ON) and the number of rhodamine-LCA positive blood vessels in
each section was visually quantified.

2.10 Human Tissue Microarray Analysis
Three tissue biopsies were taken from 49 patients who underwent surgical procedures at
L’Université de Montréal for the removal of renal masses. Two biopsies were from
diseased tissue and the third was from surrounding healthy tissue. Acquisition and
processing of formalin-fixed, paraffin-embedded samples was performed by personnel of
Dr. Jean-Baptiste Lattouf (L’Université de Montréal, Montréal, QC) and samples were
probed for CBS (rabbit anti-human CBS, Novus Biologicals, NBP1-33518) and CSE
(rabbit anti-human CSE, ProteinTech, 12217-1-AP). Digital images of stained tissue as
well as patient information were sent from the Lattouf lab to the Sener lab. Blinded
scoring of antibody staining was performed by Eric Sonke using a system advised by Dr.
Aaron Haig (Western University, London, ON). Using a scale of 0-3, samples were
scored on the degree of both diffuse and localized expression. Correlation analysis
relating protein expression to Fuhrman grade and tumour size were also performed.

2.11 Statistical Analyses
All statistical analyses were performed using GraphPad Prism v6.05 software. Figures
displaying representative data of one independent experiment show standard deviation of
the mean. Figures displaying data of multiple independent experiments show standard
error of the mean. Results from one-way ANOVA were further subjected to Tukey’s
multiple comparisons test due to unequal sample sizes between groups. Results from
two-way ANOVA were further subjected to Sidak’s multiple comparisons test (to
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optimize power), Tukey’s multiple comparisons test (in cases of unequal sample sizes)
and Dunnett’s multiple comparisons test (when comparing to an identified control).

40

3. Results
3.1 Objective I – Is Endogenous Production of H2S
Enhanced in VHL-deficient ccRCC Cell Lines?
3.1.1

Levels of H2S are increased in VHL-deficient ccRCC cell
lines

To address whether baseline H2S production is increased in VHL-deficient ccRCC,
endogenous levels of H2S were measured in two VHL-deficient ccRCC cell lines (786-O
and 769-P) and compared to a VHL WT ccRCC cell line (Caki-1) and a nonmalignant
renal cell line (HK-2). Accumulation of intracellular H2S was tracked over 15 hours
using a fluorescent H2S-specific probe in combination with live-cell imaging (Figure 3).
It was found that significant accumulation of H2S occurred in HK-2 cells (p < 0.001),
786-O cells (p < 0.0001) and 769-P cells (p < 0.0001) over 15 hours, though not in Caki1 cells (p > 0.05; Figure 3A). When compared to HK-2 cells, the accumulation of H2S in
786-O and 769-P cells after 15 hours was significantly greater (p < 0.0001), while the
accumulation of H2S in Caki-1 cells was significantly lower (p < 0.05) (Figure 3A, 1B).
Accumulation of H2S in the VHL-deficient ccRCC cell lines after 15 hours was also
significantly greater (p < 0.0001) than in the VHL WT Caki-1 cells (Figure 3A).
In an attempt to implicate VHL deficiency in the accumulation of H2S, a functional allele
of VHL was reintroduced into 786-O cells to partially restore its function. Endogenous
levels of H2S were then measured using the methylene blue assay and compared to
unmolested 786-O cells, HK-2 cells and heat-killed control cells (Figure 4). Reintroduction of VHL into 786-O cells was unable to bring levels of H2S back down to
baseline (Figure 4). Detectable levels of H2S were observed in heat-killed cells, which
highlights the non-specificity of this assay.
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Figure 3. Baseline endogenous H2S production is greater in VHL-deficient ccRCC
cell lines than in VHL WT malignant and non-malignant renal cell lines. Cells were
seeded into 96-well plates and allowed to reach 90-100% confluency. A cell-permeable
probe that reacts specifically with H2S to fluoresce green was then either added (probe),
or not added (no probe), to growth media and cells were imaged every hour for 15 hours.
Following imaging, the number of fluorescent “hits” was normalized to cell confluency
for each well and each time point, resulting in a normalized probe count which was then
averaged (n = 3, error bars represent standard deviation of the mean). Results are
representative of 3 independent experiments (n = 9 total). One-way ANOVA with
Tukey’s multiple comparisons test was used to asses statistically significant differences
between groups (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001). (A) (i) VHL
mutation status of nonmalignant renal cells (HK-2) and ccRCC cell lines (Caki-1, 769-P,
786-O). Statistically significant changes in endogenous H2S production over time
(between 0 hours and 15 hours) in each cell line. Statistically significant differences in
endogenous H2S production between cell lines. (B) Representative images of enhanced
endogenous H2S production in 786-O cells as compared to HK-2 cells.
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Figure 4. Effect of VHL knock-in on endogenous H2S production in 786-O cells, as
measured by methylene blue assay. The methylene blue assay was used to compare
endogenous H2S production in heat-killed cells (dead cells), non-malignant renal cells
(HK-2), VHL-deficient ccRCC cells (786-O), and 786-O cells with VHL knocked-in
through lentiviral transfection. One-way ANOVA with Tukey’s multiple comparisons
test revealed a lack of statistically significant differences between groups; n = 4 per cell
line (n = 1 for dead cells).
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3.1.2

VHL-deficient ccRCC cell lines do not display increased
expression of CBS, CSE, or MPST

It was hypothesized that VHL inactivation leads to increased expression of the H2Sproducing enzymes CBS, CSE and/or MPST, which in turn leads to increased cellular
levels of H2S. To answer this question, western blot analysis of CBS, CSE and MPST
was performed to determine baseline expression of these enzymes in HK-2, Caki-1, 786O and 769-P cell lines (Figure 5). There were no significant differences in baseline
normoxic expression of CBS, CSE, nor MPST (Figure 5). There was no clear trend to
suggest that VHL inactivation leads to aberrant upregulation of endogenous H2Sproducing enzymes.
To determine whether expression of CBS, CSE and/or MPST is regulated by hypoxia
through mechanisms not involving VHL/HIF-1/2α, the same cell lines were grown in
hypoxia for 6, 12 and 24 hours and protein extracted for further western blot analysis
(Figure 6). When compared to normoxic controls, expression of CBS, CSE, and MPST
did not significantly increase under hypoxia in any of the cell lines (Figure 6).
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Figure 5. Baseline normoxic expression of H2S-producing enzymes is unaltered in
VHL-deficient ccRCC cell lines when compared to malignant and non-malignant
VHL WT renal cell lines. Protein was isolated from 80-90% confluent cell cultures
grown in normoxia (21% O2) using RIPA buffer. SDS-PAGE was carried out on 40-50
μg of whole cell lysate using 10-12% poly-acrylamide gels and western blots were
performed using PVDF membranes. Blots were probed for (A) CBS (63 kDa), (B) CSE
(45 kDa) and (C) MPST (33 kDa) while β-actin (43 kDa) served as a loading control
against which protein expression was normalized. Expression of CBS, CSE and MPST in
renal cancer cell lines (Caki-1, 786-O, 769-P) was normalized to expression of these
same enzymes in the non-malignant renal epithelial cell line HK-2. Error bars represent
standard error of the mean (SEM), n = 3. Blots shown are representative of all three blots.
One-way ANOVA and Tukey’s multiple comparisons test revealed no statistically
significant differences in CBS, CSE nor MPST expression between cell lines.
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Figure 6. Hypoxic induction of H2S-producing enzymes in malignant, and nonmalignant renal cell lines. Protein was isolated from 80-90% confluent cell cultures
grown in normoxia (N; 21% O2) or hypoxia (1% O2) for 6, 12 or 24 hours (H-6, H-12, H24) using RIPA buffer. SDS-PAGE was carried out on 40-50 μg of whole cell lysate
using 10-12% poly-acrylamide gels and western blots were performed using PVDF
membranes. Hypoxic induction of CBS (63 kDa), MPST (33 kDa) and CSE (45 kDa)
was evaluated in (A) HK-2, (B) Caki-1, (C) 786-O and (D) 769-P cell lines. β-actin (43
kDa) served as a loading control against which protein expression was normalized. Error
bars represent standard error of the mean (SEM), n = 3. Blots shown are representative of
all three blots. One-way ANOVA and Tukey’s multiple comparisons test revealed a lack
of statistically significant differences in CBS, CSE and MPST expression between
treatments in all cell lines.
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To more thoroughly investigate the relationship between VHL function and hypoxic
induction of CBS, CSE and MPST, western blot analysis comparing expression of CBS,
CSE and MPST in 786-O and 786-O VHL+ cells under normoxia and hypoxia was
performed (Figure 7). When VHL function was restored to 786-O cells, expression of
CBS, CSE and MPST did not change (Figure 7). Interestingly, the hypoxic expression
profile of CSE (ratio of high molecular weight band to low molecular weight band) was
significantly altered following knock-in of VHL into 786-O cells (Figure 7B). Successful
knock-in of functional VHL (VHLwt) was also confirmed via western blot analysis
(Figure 7C).
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Figure 7. Normoxic expression and hypoxic induction of H2S-producing enzymes in
wild-type 786-O cells (786-O) and VHL knock-in 786-O cells (786-O VHL+). Protein
was isolated from 80-90% confluent cell cultures grown in normoxia (21% O2) or
hypoxia (1% O2) for 15 hours using RIPA buffer. SDS-PAGE was carried out on 40-50
μg of whole cell lysate using 10-12% poly-acrylamide gels and western blots were
performed using PVDF membranes. Normoxic expression (A) or hypoxic induction (B)
of CBS (63 kDa), MPST (33 kDa) and CSE (45 kDa) was evaluated in 786-O and 786-O
VHL+ cell lines. Validation of VHLwt (20 kDa) knock-in was performed under both
normoxia and hypoxia (C). Protein levels were expressed relative to β-actin (43 kDa), or
as a ratio of top band: bottom band (CSE, MPST) or as a ratio of functional protein:nonfunctional protein (VHL) in instances where doublet bands are presented. Error bars
represent standard error of the mean (SEM), n = 3. One-way ANOVA and Tukey’s
multiple comparisons test indicate statistically significant differences (p < 0.05) where
indicated (*).
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3.2 Objective II – Does Endogenous H2S Production
Contribute to the Proliferation, Metabolism and Survival
of ccRCC Cell Lines?
3.2.1

Endogenous H2S production can be targeted, though not
stimulated, in VHL-deficient ccRCC cell lines

The dual CBS/CSE inhibitor HA, the CSE inhibitor PAG and the substrate for
endogenous H2S production LC were administered to HK-2, Caki-1, 786-O and 769-P
cell lines to determine if they could influence baseline H2S production (Figure 8). Using
the fluorescent H2S-specific probe it was found that accumulation of H2S in HK-2 cells
significantly (p < 0.0001) increased over time when LC (blue) was added to growth
media (Figure 8A) and that this increase in H2S was significantly greater than the
increase observed in untreated cells (Figure 8B). LC was able to evoke a similar
response in VHL WT Caki-1 cells (Figure 8A, B). However, in the VHL-deficient
ccRCC cell lines, treatment with LC did not increase endogenous H2S production to the
same degree, as a result of increased baseline levels (Figure 8A, B).
As a result of their elevated baseline production of H2S, VHL-deficient ccRCC cell lines
were much more susceptible to inhibition with HA when compared to non-malignant
HK-2 cells and VHL WT Caki-1 cells (Figure 8, red). There was no significant
accumulation of H2S in HK-2 cells over 15 hours when cultured in the presence of HA
(Figure 8A) and levels of H2S in HA-treated cells were significantly (p < 0.05) lower than
in untreated cells (Figure 8B). The reductions in H2S upon HA treatment were also
significant in 769-P cells (p < 0.0001; Figure 8B) and 786-O cells (p < 0.0001; Figure
8Biv). Treatment of all cell lines with a combination of HA and LC could significantly
increase production of H2S when compared to treatment with HA alone (Figure 8, green).
Treatment with the CSE inhibitor PAG did not significantly decrease endogenous H2S
production (data not shown).
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Figure 8. Inhibition of endogenous H2S production reduces elevated levels of H2S in
VHL-deficient ccRCC cell lines. Cells were seeded into 96-well plates and allowed to
reach 90-100% confluency. A cell-permeable probe that reacts specifically with H2S to
fluoresce green was then added (or not added; ie. no probe), to growth media. At the
same time, cells were treated with either PBS vehicle (control; black) an inhibitor of
endogenous H2S synthesis (hydroxylamine (HA); 1 mM; red), the substrate for
endogenous H2S synthesis (L-cysteine (LC); 5 mM; blue) or a combination of the two (1
mM HA + 5 mM LC; green). Cells were imaged every hour for 15 hours and background
fluorescence was compensated for using thresholding. Following compensation, the
number of fluorescent “hits” was normalized to cell confluency for each well and each
time point, resulting in a normalized probe count which was then averaged (n = 3, error
bars represent standard deviation of the mean). Results are representative of 3
independent experiments (n = 9 total). One-way ANOVA with Tukey’s multiple
comparisons test was used to asses statistically significant differences between groups (*
p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001). (A) Statistically significant
changes in endogenous H2S production over time (between 0 hours and 15 hours) were
determined for each treatment in HK-2, Caki-1, 769-P and 786-O cells. (B) Statistically
significant differences in endogenous H2S production between treatments were
determined in each cell line.
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3.2.2

Endogenous H2S production contributes to the proliferation
of ccRCC cell lines

Cells were treated with HA and cell confluency was tracked over 15 hours using live-cell
imaging to determine whether endogenous H2S production plays a role in mediating cell
growth (Figure 9). HA treatment did not significantly restrict the growth of HK-2 cells
(Figure 9). Significant (p < 0.05) restriction of cell growth was observed in Caki-1 cells,
769-P cells and 786-O cells, though not in 786-O VHL+ cells (Figure 9). While higher
concentrations of HA (1 mM) were cytotoxic to ccRCC cell lines, lower concentrations
of HA (0.1 mM) actually slightly stimulated cell growth (data not shown). As such, there
is a narrow range in which inhibition of endogenous H2S production can restrict cell
growth. There was no clear relationship between VHL inactivation, and reliance on H2S
for cell growth (Figure 9).
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Figure 9. Inhibition of endogenous H2S production attenuates proliferation of
ccRCC cell lines. Cells were seeded into 96-well plates and allowed to reach 40-60%
confluency. Cells were treated with either PBS vehicle (control; black) or an inhibitor of
endogenous H2S synthesis (hydroxylamine (HA); 0.5 mM; red). Cells were imaged
every hour for 12 hours and phase confluency was measured. (A) Following imaging,
percentage change in cell confluency was determined for each well and averaged for each
time point (n = 3, error bars represent standard deviation of the mean). Results are
representative of 2 independent experiments (n = 6 total). Multiple t-tests were used to
asses statistically significant differences between groups at T = 12 hours (* p < 0.05).
(B) Representative images depicting inhibition of cell proliferation following 12 hour
treatment with HA.
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3.2.3

Endogenous H2S production contributes to the survival of
ccRCC cell lines

Cells were treated with HA and PAG to determine whether loss of endogenous H2S
production impacts 48 hour cell survival under normoxic and hypoxic conditions, as
determined by Annexin-V-PE and 7-AAD detection (Figure 10). Under normoxic
conditions all ccRCC cell lines were found to be significantly (p < 0.05) more susceptible
to treatment with HA than HK-2 cells (Figure 10A,C). Caki-1 and 786-O cell lines were
also significantly (p < 0.05) more susceptible to treatment with HA than HK-2 cells under
hypoxic conditions, however 769-P cells were not (Figure 10A). The reduction in
hypoxic viability of HK-2 cells was significantly (p < 0.05) greater than the reduction in
normoxic viability (Figure 10B), while the opposite was true of the ccRCC cell lines
(Figure 10D). Inhibition of CSE alone, through use of the inhibitor PAG, proved to be
less effective in reducing viability than inhibition of CBS and CSE through use of the
inhibitor HA (Figure 10D). The only cell line to display significant declines in viability
following PAG treatment was the ccRCC cell line 769-P (Figure 10D).
When treated with a combination of HA and LC, the VHL-deficient ccRCC cell lines
769-P and 786-O displayed significant (p < 0.05) restoration of viability when compared
to treatment with HA alone (Figure 10E). The same could not be said of the VHL WT
Caki-1 cell line.
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Figure 10. Inhibition of endogenous H2S production selectively kills ccRCC cells
over non-malignant renal cells. Cells were treated for 48 hours with inhibitors of
endogenous H2S production hydroxylamine (HA) and propargyl glycine (PAG) and/or
the substrate for endogenous H2S production L-cysteine (LC) in normoxic (21% O2) or
hypoxic (1% O2) growth conditions. Cell culture viability was determined via detection
of Annexin-V-PE and 7AAD using flow cytometry and quantified relative to the
untreated, normoxic cells within each experimental trial. Error bars represent standard
error of the mean (SEM). Two-way ANOVA with Dunnett’s multiple comparisons test
was used to asses significant differences between groups (i.e. normoxic control vs.
hypoxia control; †; p < 0.05). Two-way ANOVA with Sidak’s multiple comparisons test
was used to assess significant differences between treatments within groups (i.e.
normoxic control vs. normoxic 4 mM HA; *; p < 0.05). (A) ccRCC cell lines are more
susceptible to treatment with HA than non-malignant HK-2 cells, n = 6-9. (B) HK-2 cells
are susceptible to treatment with HA, however hypoxic viability is impacted more-so
than normoxic viability, n = 6. (C) Representative flow cytometry dot plots illustrating
changes in normoxic viability of cell lines following treatment with 4 mM HA, as
quantified in (A). (D) Differential susceptibility of ccRCC cell lines to treatment with
HA and PAG (Caki-1, n = 6-8; 769-P, n = 6-12; 786-O, n = 6-10). (E) VHL-deficient
ccRCC cell lines treated with HA and LC simultaneously display attenuated declines in
viability (Caki-1, n = 3-6; 769-P, n = 3-8; 786-O, n = 4-6).
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3.2.4

Endogenous H2S production contributes to the metabolism
of ccRCC cell lines

To determine if declines in viability upon inhibition of endogenous H2S production were
the result of deficits in metabolic activity, the XTT cytotoxicity assay was used to
measure alterations in metabolic activity after 48 hour treatment (Figure 11). It was
observed that the VHL-deficient cell lines 786-O and 769-P suffered significant declines
in metabolic activity upon treatment with HA (p < 0.05) while the VHL wild-type cell
lines HK-2, Caki-1 and 786-O VHL+ did not (Figure 11). As with the viability assays,
combination treatment with HA and LC resulted in significant (p < 0.05) restoration of
hypoxic metabolic activity compared to HA treatment alone in the VHL-deficient ccRCC
cell lines 786-O and 769-P (Figure 11). Combination treatment with HA and LC also
resulted in significant (p < 0.05) differences between normoxic and hypoxic viability in
all ccRCC cell lines, but not HK-2 cells (Figure 11).
The XTT assay measures mitochondrial metabolism based on the activation of coenzyme
Q by NADH and other electron donors. In order to quantitate how H2S production may
be contributing to forms of metabolism that do not rely on electron transport, total ATP
was measured following 6 hour treatments administered under normoxia and hypoxia
(Figure 12). Unexpectedly, hypoxic ATP production was significantly (p < 0.05) higher
than normoxic ATP production for HK-2 cells (Figure 12). Inhibition with HA
significantly (p < 0.05) decreased normoxic and hypoxic ATP production in all HK-2
cells, 786-O cells and 786-O VHL+ cells (Figure 12). Combined treatment with HA and
LC could not restore ATP production in any of the cell lines, contrary to results of the
XTT assay (Figure 12).
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Figure 11. Inhibition of endogenous H2S production reduces overall metabolic
activity of ccRCC cell lines. Metabolic activity was assessed via the XTT assay
following 48 hour treatment with hydroxylamine (HA), L-cysteine (LC) or a combination
of both. Values are presented as relative to the untreated, normoxic cells within each
experimental trial. Error bars represent standard error of the mean (SEM). HK-2 (n = 6),
Caki-1 (n = 6), 786-O VHL+ (n = 6), 769-P (n = 5-6), 786-O (n = 5-6). Two-way
ANOVA with Dunnett’s multiple comparisons test was used to asses significant
differences between groups (normoxic control vs. hypoxia control; †; p < 0.05). Twoway ANOVA with Sidak’s multiple comparisons test was used to assess significant
differences between treatments within groups (normoxic control vs. normoxic 4 mM HA;
*; p < 0.05).
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Figure 12. Inhibition of endogenous H2S production reduces ATP production in
malignant and non-malignant renal cell lines. Total cellular ATP was assessed using a
luciferin/luciferase-based assay following 6 hour treatment with hydroxylamine (HA), Lcysteine (LC) or a combination of both. ATP concentration was normalized in each
sample using protein concentration and then averaged (n = 3, error bars represent
standard deviation of the mean). Results are representative of 2 independent experiments
(n = 6 total). Two-way ANOVA with Dunnett’s multiple comparisons test was used to
asses significant differences between groups (normoxic control vs. hypoxia control; †; p
< 0.05). Two-way ANOVA with Sidak’s multiple comparisons test was used to assess
significant differences between treatments within groups (normoxic control vs. normoxic
4 mM HA; *; p < 0.05).
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3.3 Objective III – Does Endogenous H2S Production
Contribute to the Neovascularization of ccRCC
Xenografts?
3.3.1

Inhibition of endogenous H2S production restricts the
neovascularization of ccRCC xenografts

H2S is known to participate in paracrine angiogenic signalling and has been shown to
play a role in the vascularization of other cancers. To investigate the effects of
endogenous H2S production on the vascularization of ccRCC tumours, the chick
chorioallantoic membrane (CAM) was used as a vascular structure for xenograft
implantation of ccRCC cell lines. Cell lines were manipulated to express EGFP and
chick vasculature was labelled with rhodamine-labelled lens culinaris agglutinin
(rhodamine-LCA) such that the number of intratumoural blood vessels could be
quantified using fluorescent microscopy. Treatments were injected IV for four
consecutive days following two days of initial tumour growth and then harvested,
sectioned and imaged (Figure 13).
Treatment with HA was able to significantly (p < 0.05) decrease the vascularization of
the VHL-deficient 786-O and 769-P xenografts while the same treatment had no effect on
the vascularization of VHL wild-type Caki-1 xenografts (Figure 13). Treatment with LC
was able to significantly (p < 0.05) increase the number of intratumoural blood vessels
(Figure 13A) and also appeared to dilate blood vessels (Figure 13B). When 786-O and
769-P xenografts were treated with a combination of HA and LC simultaneously, the
decline in vascularization observed with HA treatment alone was attenuated (Figure 13).
Knock-in of VHL into the 786-O cell line not only decreased overall vascularization of
untreated xenografts, but also appeared to eliminate the cells’ sensitivity to HA and LC
treatment (Figure 13).
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Figure 13. Systemic inhibition of endogenous H2S production with hydroxylamine
(HA) reduces the vascularization of VHL-deficient ccRCC xenografts. ccRCC cell
lines were xenografted into the CAM of 9-day old chicken embryos and given 2 days to
establish themselves within the surrounding tissue. Embryos were then systemically
treated once a day for 4 days with 50 μL of 20 mM hydroxylamine (HA), 10 mM Lcysteine (LC) or a combination of both (HA + LC) through intravascular microinjection.
Prior to harvest, embryos were systemically injected with rhodamine-conjugated lens
culinaris agglutinin (rhodamine-LCA) to label all chick vasculature. (A) The number of
rhodamine-LCA-positive blood vessels present in each field of view shot was counted
manually following confocal imaging at 200X total magnification. Error bars represent
standard error of the mean (n ≥ 30 per treatment). One-way ANOVA with Dunnet’s
multiple comparisons test was used to assess statistical significance of treatments
compared to PBS vehicle control (*; p < 0.05). (B) Representative images of data
depicted in (A). Rhodamine-LCA-positive blood vessels (red) are seen in close
proximity to EGFP-expressing RCC cells (green). Scale bar represents 100 μm.
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3.3.2

Inhibition of endogenous H2S production restricts the growth
of ccRCC xenografts

Similar trends were observed when analyzing the effect of H2S production on tumour
growth as measured by cross-sectional area of whole tumours prior to harvest (Figure
14). HA treatment was able to significantly (p < 0.05) decrease the size of 769-P
xenografts, but not the size of 786-O xenografts (Figure 14). Conversely, HA treatment
had no effect on the cross-sectional area of VHL WT Caki-1 and 786-O VHL+
xenografts (Figure 14). As with vascularization, treatment with HA and LC
simultaneously was able to attenuate the decrease in size in 786-O and 769-P xenografts
(Figure 14). Qualitative inspection of tumours revealed that HA treatment also resulted
in necrotic and dysmorphic tumours (Figure 14B).
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Figure 14. Systemic inhibition of endogenous H2S production with hydroxylamine
(HA) restricts the growth of VHL-deficient ccRCC xenografts. ccRCC cell lines
were xenografted into the CAM of 9-day old chicken embryos and given 2 days to
establish themselves within the surrounding tissue. Embryos were then systemically
treated once a day for 4 days with 50 μL of 20 mM hydroxylamine (HA), 10 mM Lcysteine (LC) or a combination of both (HA + LC) through intravascular microinjection.
Prior to harvest, fluorescent stereoscope images were obtained for each tumour. (A) The
cross-sectional area of stereoscope images (20X) of each tumour was measured using
ImageJ software. Error bars represent standard error of the mean (n ≥ 10 per treatment).
One-way ANOVA with Dunnet’s multiple comparisons test was used to asses statistical
significance of treatments compared to PBS vehicle control (*; p < 0.05). (B)
Representative images of data depicted in (A). zsGreen expression (green) was used to
identify RCC cells. Scale bar represents 1 mm.
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3.4 Objective IV – Is Endogenous H2S Production
Enhanced in Human ccRCC Tumours?
3.4.1

Expression of CBS or CSE is not upregulated in human
ccRCC tumours

In an attempt to link increased endogenous H2S production to the progression of actual
ccRCC tumours, patient-matched renal biopsies of healthy and diseased tissue were
probed for CBS and CSE. Antibody staining was scored on a scale of 0-3 for intensity of
localized (punctate dots) and diffuse (hazy, non-specific) expression. When all tumours
were analyzed together – without being sub-classified as benign, malignant, non-ccRCC
or ccRCC – diseased tissue had significantly (p < 0.0001) lower diffuse expression of
both CBS and CSE, whereas localized expression was maintained (Figure 15A). The
same trend applied when tumour classes of benign (Figure 15B), malignant (Figure 15C)
and ccRCC (Figure 15D, E) were analyzed individually.

3.4.2

Expression of CBS or CSE is not correlated with Fuhrman
grade or tumour size

To determine whether expression of CBS and CSE were in some way correlated with
prognostic factors of ccRCC, correlation analyses were performed for staining
intensity/Fuhrman grade, as well as staining intensity/tumour size. When localized
expression of CBS and CSE was plotted against Fuhrman grade, no significant
correlation was apparent (CBS: r = -0.044; CSE: r = 0.272). Diffuse expression of CBS
and CSE was also not correlated with Fuhrman grade (CBS: r = 0.085; CSE r = -0.043).
There was also no correlation between tumour volume and diffuse/localized expression
of CBS (diffuse: r = -0.153; localized: r = -0.135) and CSE (diffuse: r = 0.008; localized:
r = 0.171). Clinical details of patient samples are available in Appendix A.
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Figure 15. Diffuse and localized expression patterns of CBS and CSE in human
renal tumour samples. Patient-matched biopsies from healthy (normal, n = 1 per
patient) and diseased (tumour, n = 2 per patient) renal tissue were fixed, paraffin
embedded into tissue microarray blocks, sectioned and immunohistochemically probed
for both CBS and CSE. Images of stained sections were scored for both intensity of
diffuse expression (diffuse) and intensity of localized expression (localized) on a scale of
0-3 in a blinded fashion. Error bars represent standard error of the mean (SEM). Oneway ANOVA with Tukey’s multiple comparisons test was used to asses statistically
significant differences between groups (** p < 0.01; *** p < 0.001; **** p < 0.0001).
Data were categorized by tumour type: (A) All tumours, n = 49 normal sections, n = 98
tumour sections; (B) Benign tumours, n = 7 normal sections, n = 14 tumour sections; (C)
Malignant tumours, n = 42 normal sections, n = 84 tumour sections; (D) Clear-cell
tumours, n = 27 normal sections, n = 54 tumour sections. (E) Representative expression
patterns of CBS and CSE in normal and ccRCC tissue samples. Note in ccRCC samples
the loss of diffuse CBS and CSE expression but maintenance of intensely staining puncta.
Scale bar represents 100 μm.
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4. Discussion
4.1 Relation to Initial Hypothesis
In order for something to accumulate, the rate of its production must exceed the rate of its
removal. Our understanding of endogenous H2S production by CBS, CSE and MPST is
in its infancy, and our understanding of H2S removal via mitochondrial oxidation is even
less well-developed. It was originally hypothesized that endogenous production of H2S
would be increased in ccRCC cell lines lacking a functional copy of the VHL tumour
suppressor, as a result of HIF-1/2α-mediated upregulation of H2S-producing enzymes.
While levels of H2S were elevated in VHL-deficient ccRCC cell lines, it was not due to
increased expression of the enzymes responsible for H2S production – CBS, CSE and
MPST. The most likely explanation for this result is that loss of VHL function and HIF1/2α accumulation results in decreased mitochondrial biogenesis and respiration (55),
thus eliminating the primary mechanism of H2S removal – mitochondrial oxidation.
Therefore, while VHL inactivation and HIF-1/2α accumulation does not influence H2S
production by inducing expression of CBS, CSE and MPST, VHL inactivation and HIF1/2α accumulation likely influence H2S removal by decreasing overall mitochondrial
activity.
The efficacy of targeted therapies for cancer treatment lies in the cancer possessing some
trait that non-malignant cells do not possess. Targeted therapies that have been
developed for treatment of ccRCC are clinically effective due to their ability to
specifically target these traits with relatively mild adverse effects (42). However, while
specificity of action is desired with any treatment, it inherently limits the range of cellular
processes that are subject to inhibition. In the case of ccRCC, today’s clinical therapies
are unable to concurrently target tumour cell growth/survival and the tumour’s
angiogenic potential (11). While the targeted approach has been shown to be a sound
one, the identification of new targets that may be mediating multiple aspects of disease
should continue to be pursued.
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Here it has been shown that targeting the endogenous production of H2S can reduce the
proliferation, survival, metabolic output, and angiogenic potential of ccRCC cell lines,
with minimal effects on non-malignant cells treated in vitro and in vivo. This presents
endogenous H2S-production as a valuable target in ccRCC, which when inhibited restricts
multiple facets of cancer progression.

4.2 VHL, H2S and Oxygen Sensing
The VHL tumour suppressor is a key component of the cellular response to hypoxic
growth conditions. Since O2 is essential for ATP production through oxidative
phosphorylation, cells must rely on glycolysis for ATP production under hypoxic or
anaerobic conditions. Through evolution, eukaryotic cells have also come to realize that
a drop in O2 concentration is usually due to disruption of blood supply, so hypoxic cells
secrete factors to stimulate the growth and attraction of new blood vessels. The shift in
metabolism and angiogenic response under hypoxia are both mediated by VHL, and
unintentional triggering of these responses occurs in the majority of ccRCC tumours as a
result of complete loss of VHL function (16). The perceived hypoxia, or pseudohypoxia
of ccRCC tumours has been well-documented (14), however loss of VHL function alone
does not lead to the formation of ccRCC tumours and holds no value as a prognostic
indicator of disease (22,23).
There is much evidence to support that endogenous H2S acts as an oxygen sensor in
many eukaryotes, including humans, and as such it has many things in common with the
VHL/HIF-1/2α pathway (62). H2S is constantly being produced by cells throughout the
body (64), and in turn it is removed by mitochondria in an oxygen-dependent fashion
(122). Thus under normoxia, mitochondrial oxidation of H2S is high and levels of H2S
remain low, ensuring that oxidative phosphorylation can continue without being inhibited
by H2S at Complex IV of the ETC (63,121). However under hypoxia, mitochondrial
oxidation of H2S is impaired and H2S accumulates within the cell where it can directly
influence cell signaling through post-translational modification of proteins through
cysteine (S)-sulfhydration (102). S-sulfhydration of GAPDH increases its glycolytic
activity by 700%, thus ensuring that the cell can satisfy its demand for ATP in the
absence of oxidative phosphorylation (102). H2S accumulation under hypoxia also
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affects endothelial cells through paracrine S-sulfhydration of PDE5 and KATP channels
which are necessary events in vasodilatory and angiogenic signalling pathways that aim
to restore blood supply (107,108).
If both the VHL/HIF-1/2α pathway and H2S production/oxidation pathway are
mechanisms of sensing and responding to hypoxia, then surely ccRCC tumours can
become pseudohypoxic when either pathway, or both pathways, become dysfunctional.
In fact, loss of VHL function and HIF-1/2α accumulation in ccRCC may also be
responsible for the loss of mitochondrial oxidation of H2S, which provides a link between
these two oxygen-sensing pathways in ccRCC. Baseline measurements of H2S were
shown to be higher in VHL-deficient ccRCC cell lines than in VHL WT ccRCC cell
lines. This would suggest that these two pathways are linked. Decreased mitochondrial
biogenesis, respiration and overall O2 consumption has been reported in ccRCC through
various mechanisms involving HIF-1/2α accumulation, which further supports this link
(55,56).

4.3 Crosstalk between HIF-1/2α and H2S
There has been evidence to suggest that in addition to decreased mitochondrial oxidation
of H2S under hypoxia, levels of H2S also increase under hypoxia as a result of HIF-1/2αmediated induction of CBS (99). While there did not appear to be aberrant upregulation
of CBS, CSE, nor MPST in VHL-deficient ccRCC cell lines, there was a slight (though
not significant) decrease in CBS and CSE expression when VHL function was restored to
786-O cells. It is unlikely that such drastic differences in endogenous levels of H2S
observed between VHL WT and VHL-deficient cell lines can be explained by this
modest change in CBS and CSE expression. However, it is possible that HIF-1/2αmediated control over CBS and CSE is contributing in some small way to increased
production of H2S. Perhaps hypoxic induction of CBS and CSE is of greater use in cells
that display relatively low baseline normoxic expression of these enzymes, when
compared to renal epithelial cells that display high baseline normoxic expression (86).
HIF-1/2α transcription factors may not play an important role in regulating the expression
of CBS, CSE and MPST, however that is not to say that HIF-1/2α doesn’t regulate the
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activity of CBS, CSE and MPST. Measurement of enzyme activity in cell lines with
different HIF-1α and HIF-2α expression profiles was not undertaken here due to a lack of
equipment required for such biochemical assays. However, differences in relative
expression of the upper and lower bands of CSE and MPST were observed in western
blot analysis of 786-O cells with and without functional VHL. While the changes that
these bands represent in terms of protein structure and function have not been
investigated, it is possible that they may represent differences in enzyme activity, or even
differences in enzyme localization. CSE has been shown to translocate to mitochondria
in response to various stressors, and others have shown that this translocation/stress is
associated with slight changes in the appearance of the band in western blots (123). In
contrast, there is also evidence to suggest that H2S being produced by CBS, CSE and
MPST may reciprocally alter HIF-1/2α activity (143), which could have implications on
how ccRCC progresses.
As stated previously, loss of VHL function can result in tumours that overexpress HIF-1α
and HIF-2α to varying degrees, leading to H1H2 and H2 tumours (24,26). These two
subsets of VHL-deficient ccRCC tumours have been shown to be unique with regards to
their preferred metabolic and proliferative pathways due to the differences in how HIF-1α
and HIF-2α interact with other oncogenes like c-MYC and MXI1 (24,55). It is well
accepted that one of the key steps in ccRCC progression is loss of VHL function, which
results in VHL-deficient tumours with the H1H2 phenotype (24). Recent evidence
suggests that loss of HIF-1α – resulting in the more aggressive H2 phenotype – may be
another key event in ccRCC progression, although the mechanism by which HIF-1α is
lost is unknown (9,18,30). Exogenous H2S has been shown to reduce both the
translational expression, and the activity of HIF-1α (143), however this effect has been
shown to be dependent on VHL function and mitochondrial activity (144). Interestingly,
H2S-mediated HIF-1α degradation also only occur under true hypoxic conditions – not in
response to hypoxia-mimetics, nor in pseudohypoxic RCC cell lines (144). There is also
evidence that a reducing environment can enhance the stability of HIF-2α, although the
effects of a reducing environment on HIF-1α stability were not investigated (145).
Further investigation into whether increased levels of endogenous H2S plays a role in loss
of HIF-1α in ccRCC is required.
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4.4 H2S in ccRCC Proliferation, Metabolism and Survival
There are dynamic relationships that exist between cell growth, proliferation, metabolism
and survival. On the surface these relationships may seem obvious – through
metabolism, cells generate energy and molecules that are needed to grow in size,
proliferate and survive in general (53). It is only after considering the various trade-offs
that exist between these variables that one realizes the complex decisions that cells make
on a minute-to-minute basis. For example, different growth factors stimulate different
proliferative and metabolic pathways, which generate variable levels of ROS. The degree
of ROS production in turn affects the activity of these proliferative pathways and, if
excessive, can induce a cell to undergo apoptosis. These relationships become even more
counter-intuitive in the context of cancer, where due to mutations, the cancer cell can no
longer recognize the value on either side of the trade-off, and does not react the way a
normal cell would (53).
Here we showed that H2S production contributes to the enhanced proliferation observed
in ccRCC cell lines, and targeting its production can slow, and even stop, proliferation.
Exogenous H2S has been shown to play a role in the cell cycle entry and proliferation of
colonocytes through increased production of NADPH, activation of mitogen-activated
protein kinase and Akt signalling pathways, and inactivation of the cell-cycle inhibitor
p21 (130,146). Likewise, inhibition of endogenous H2S synthesis can slow the
proliferation of ovarian cancer and colon cancer cell lines (131,133). It was observed
here that the range of concentrations, as well as treatment time, at which the CBS/CSE
inhibitor halted proliferation before becoming cytotoxic was small. As the length of
treatment time and/or concentration of the inhibitor increased, loss of H2S production
resulted in decreased metabolic activity, decreased ATP production, and ultimately
apoptosis and necrosis. Seeing as loss of H2S production was ultimately cytotoxic in
ccRCC cell lines and not simply cytostatic, one is led to believe that it plays an important
role in energy production. As observed here, a slight decrease in H2S production results
in a small deficit in energy production and influences the cell to stop dividing in order to
maintain essential survival processes. However, a greater decrease in H2S production
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results in a significant deficit in energy production to the point where the cell can no
longer maintain essential processes and dies.
In this study, energy production – metabolism – was measured using two different assays
– the XTT assay and total ATP quantitation. The XTT assay measures metabolic activity
by quantifying the turnover of electron carriers that donate electrons to coenzyme Q.
This would include NADH, flavin adenine dinucleotide, and, in the context of H2S, SQR
(122). Here it was found that the VHL-deficient ccRCC cell lines not only produced
higher levels of H2S than their VHL WT counterparts, but were also more susceptible to
metabolic inhibition with HA. Given the lack of mitochondrial respiration in VHLdeficient ccRCC cell lines, it is likely that inhibiting H2S production resulted in a
decrease in glycolytic activity, and decreased NADH production by LDH. This is
supported by results of the ATP assay, in which loss of H2S production drastically
reduced both hypoxic and normoxic ATP levels. Others have reported that H2S mediates
its metabolic effects in cancer by donating electrons to the ETC through mitochondrial
oxidation (131,133). However if this was the case in ccRCC, one would have expected
that metabolic inhibition would only have been achieved under normoxic conditions,
seeing as mitochondrial oxidation requires oxygen (122). This isolated decline in
normoxic metabolism was not observed in the VHL-deficient cell lines, but was observed
when VHL was reconstituted into 786-O cells.
Results of the ATP assay did not entirely agree with results of the XTT assay. HK-2
ATP levels were significantly reduced upon HA treatment, however no significant
difference was apparent in the XTT assay. This could be due to the fact that the ATP
assays were 6 hours in length whereas the XTT assays were 48 hours in length. Also,
H2S has been shown to reverse the flow of electrons through Complex I of the ETC,
forcing Complex I to take electrons from coenzyme Q and reduce NAD+ into NADH
(122). This allows the cell to oxidize H2S before it becomes toxic, while at the same time
keeping the pool of available NADH high. In this way, H2S could still be contributing to
ATP production in nonmalignant renal epithelial cells – as was seen here and elsewhere
(122). However, loss of H2S oxidation would not be apparent in an XTT assay since loss
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of Complex I reversion would not change the level of coenzyme Q activation – coenzyme
Q would just be oxidized by NADH instead of SQR.
The XTT assay also showed that decreased metabolism upon HA treatment could be
rescued in VHL-deficient cell lines when LC was also present in growth media. This
rescuing effect was not seen in the ATP assay, however it was observed in the flow
cytometry viability assays. In addition to its role in the ETC and metabolism, coenzyme
Q also serves antioxidative functions within the plasma membrane, playing a role in the
oxidative stress response (147). Therefore, a positive signal in the XTT assay can also
indicate increased antioxidative activity, increased resistance to oxidative stress, and
improvement in survival. It is known that the metabolic reprogramming in VHLdeficient ccRCC helps to keep oxidative stress in check by rerouting certain glycolytic
intermediates towards the production of NADPH (53). NAD+ levels must also remain
high in order for aerobic glycolysis to function (137), which is thought to be largely
accomplished by LDH in ccRCC (55). Recent evidence has shown that production of
H2S in other cancers is a crucial component of the aerobic glycolysis energy circuit that
reduces oxidative stress and contributes to ATP production by maintaining production of
NAD+ (138,139). Therefore, in helping to maintain the supply of NAD+ that fuels
aerobic glycolysis in ccRCC, H2S may also ensure that production of the antioxidant
NADPH also remains high.
As has been seen in studies of ovarian cancer (133) and colon cancer (131), increasing
concentration of inhibitors of CBS and CSE results in a steep drop off in ccRCC cell
viability. Interestingly, most of the cell lines investigated here were not susceptible to
inhibition with PAG – which specifically inhibits CSE – despite the fact that all cell lines
expressed similar levels of CSE. Cell lines were much more susceptible to inhibition
with HA – a dual inhibitor of CBS and CSE – and cell survival was observed to drop
steeply around 4 mM (140). Analysis of the flow cytometry plots displaying the
proportions of apoptotic and necrotic cells reveals that the majority of cell death is due to
necrosis that occurs following 24 hour treatment with 2-4 mM HA. Such a sudden
decline in viability suggests that at this concentration of the CBS/CSE dual inhibitor,
levels of H2S have declined to a point where the cell can no longer perform essential
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processes and/or can no longer cope with the oxidative stress being applied. This is
supported by the observation that in ccRCC cell lines viability was more severely
impacted under normoxic conditions when levels of oxidative stress are higher.
Similarly, others have shown that addition of the antioxidant glutathione can attenuate
declines in viability seen following loss of H2S production (133).

4.5 H2S in ccRCC Angiogenesis
VHL-deficient ccRCC tumours are highly angiogenic as a result of high VEGF secretion
that is driven by upregulation of both HIF-1α and HIF-2α (17,27). VEGF secretion has
been shown to be positively correlated with the size, vascularization, stage and Fuhrman
grade of ccRCC tumours and has great prognostic value (148). The efficacy of
bevacizumab and various RTKIs in the clinical setting speaks to the importance of
VEGF-mediated angiogenesis in ccRCC progression both prior to and following
metastasis (11). Multiple sources of evidence suggest that VEGF-mediated angiogenesis
is dependent upon tonic inhibition of PDE5 by H2S in endothelial cells (107-109,149).
Other mechanisms by which H2S exerts its pro-angiogenic effects have also been
suggested (71,149). ccRCC xenograft vascularization assays performed here support
these lines of evidence.
It was found that the attraction of blood vessels towards VHL-deficient ccRCC
xenografts could be reduced upon systemic inhibition of endogenous H2S production. It
could not be determined whether the intravascularly-injected inhibitor was targeting H2S
production in endothelial cells or in the cancer cells themselves. The VHL-deficient
xenografts were observed to decrease in size following HA treatment which could
indicate direct cytotoxicity of the treatment, and suggest that H2S production was being
targeted in the tumour. However, the decrease in xenograft size could also have been the
effect of being starved of nutrients that aren’t being supplied due to devascularization,
which would suggest that treatments failed to reach the tumour are were acting on
endothelial cells. Others have shown that chick endothelial cells are susceptible to
inhibition of endogenous H2S production within the CAM vasculature (71).
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Interestingly, the vascularization of VHL WT xenografts was shown to not be susceptible
to inhibition of H2S production. These cell lines have been shown to secrete lower levels
of VEGF and were, on average, less well vascularized than their VHL-deficient
counterparts (26,27). The VEGF-mediated vascularization of these tumours plays less of
a role and this is likely why the inhibitor was not effective. The fact that the inhibitor had
no effect on the vascularization of xenografts secreting lower levels of VEGF lends
credence to the role of H2S in VEGF-mediated angiogenesis. Of further interest,
systemic treatment with LC resulted in noticeable vessel vasodilation, but only when
these vessels were in close proximity to VHL-deficient xenografts. This would suggest
that the treatments are acting directly on the cancer cells, resulting in changes in tumourderived H2S that affects the surrounding vasculature through paracrine signalling.

4.6 Translational Applications
In this study, it has been shown that inhibition of endogenous H2S production can target
multiple aspects of ccRCC disease progression, making it a potentially promising
treatment option of mRCC. Depending on the dosage of treatment, the dual CBS/CSE
inhibitor preferentially targeted the proliferation, metabolism, and survival of ccRCC cell
lines over non-malignant renal epithelial cells in vitro. Furthermore, systemic
intravascular injection of the inhibitor was able to decrease the vascularization of ccRCC
xenografts without impacting the survival of chick embryos. Some of these effects were
observed in both VHL WT and VHL-deficient cell lines, and some were observed
regardless of VHL status. When translating these findings to the clinical setting, it will
be important to identify markers that are more predictive of therapeutic efficacy than
VHL-deficiency seems to be (148). As was observed in ccRCC cell lines, human ccRCC
tumours did not display increased expression of H2S-producing enzymes when compared
to normal tissue, therefore total expression of CBS, CSE and MPST may not be helpful in
this regard. However, interesting localization patterns of CBS and CSE were observed in
ccRCC which could be of prognostic value or provide insight into the role of H2S in
ccRCC progression.
While stage IV mRCC has often been the focus when developing new therapies against
ccRCC, (neo)adjuvant therapies for treatment of stage II and stage III ccRCC have not
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been a priority (36). Many of these diseases have a high risk of relapsing within 5 years
of surgical resection and this contributes heavily to disease mortality (36). The cellular
source of cancer relapse is currently unknown, although there is strong evidence to
suggest that cancer stem cells may be responsible for this relapse in ccRCC and other
cancers (150). Recent work has shown that the production of H2S plays a key role in
maintaining the stem-like phenotype of cancer cells through induction of stem cell factors
OCT4 and NANOG, and through regulation of cellular energy production and oxidative
stress (139). Endogenous H2S production was also associated with the spheroid-forming
and transdifferentiation potential of cells, which are thought to be important processes in
disease relapse (139). Treatment with inhibitors of H2S synthesis either before or after
nephrectomy might limit the ability of any remaining cancer cells to form new tumours.
One of the challenges of treating mRCC is its resistance to well-established, costeffective, readily-available systemic therapies such as chemotherapy and radiation
therapy (8). It has been shown that chemopreventive agents – agents that limit the
efficacy of chemotherapies – often increase the antioxidative potential of cancer cells
through increased production of glutathione and NADPH and increased activity of Nrf2
(151,152). S-Sulfhydration of Keap1 – a protein that suppresses Nrf2 – has been shown
to prevent the inhibitory effects that Keap1 has on Nrf2, thus increasing the antioxidative
response (96). Additional antioxidative properties of H2S include increased production of
reduced glutathione and polysulfides (67,115), which may be involved in conferring
chemoresistance in ovarian cancer (133). Also, hypoxia-induced radioresistance may be
mediated by the cytoprotective effects of H2S accumulation under hypoxic conditions
(134,135). Together, there is much evidence to support that inhibition of endogenous
H2S production may enhance conventional forms of systemic therapy and should be
investigated further.
While targeted therapies have been shown to improve PFS and ORR of patients afflicted
with mRCC, durable complete responses remain elusive and therapy resistance remains
an issue (41,42). Cancer therapies apply a selective pressure on tumours which may or
may not affect all cells within a tumour. Those cells that are more resistant to the applied
pressure are more likely to survive and proliferate, whereas the cells that are affected by
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the treatment are removed. With successive rounds of therapy, the composition of the
tumour changes such that most of the cells are resistant to the applied pressure, and the
therapy becomes ineffective. This process called tumour progression applies to various
selective pressures – such as hypoxia, nutrient deprivation and oxidative stress – that
occur naturally as the tumour grows in size and composition (136). Endogenous
production of H2S seems to facilitate recovery from these selective pressures that arise
throughout the course of tumour progression (137,138). It would be interesting to
determine whether cells that develop resistance to targeted therapies also produce higher
levels of H2S. If so, combining inhibitors of endogenous H2S production with recently
developed targeted therapies could delay the onset of resistance in mRCC. Similar
reasoning suggests that inhibition of endogenous H2S production might be a form of
therapy that ccRCC tumours are less inclined to develop resistance to, although export of
the inhibitors by P-glycoprotein remains a possibility (8).

4.7 Recommendations
The results of this study have exposed multiple avenues for future research. First and
foremost, while the use of a dual CBS/CSE inhibitor has provided valuable information
regarding the adverse effects of such a drug when used in vitro and in vivo, siRNA- or
shRNA-mediated knockdown of CBS, CSE and MPST would be more valuable in
determining the importance of each of these three enzymes. There are currently no bona
fide MPST inhibitors, and the dual CBS/CSE inhibitor used here has its limitations (140).
Generation of cell lines with each of CBS, CSE and MPST knocked out using shRNA
would be ideal in that it would allow for longer experiments both in vitro and in vivo,
although knocking out each enzyme in all cell lines investigated here would be quite
time-consuming. However, it may be the only way to determine if one of these H2Sproducing enzymes is more important than the others, which can then drive the
development of specific inhibitors.
In this study, the elevated level of H2S in VHL-deficient ccRCC cell lines was explained
by decreased mitochondrial biogenesis and activity. While reduced mitochondrial
activity and biogenesis has been observed in ccRCC (153), and it is known that the
majority of ccRCC tumours are VHL-deficient (1), the mechanisms linking
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mitochondrial metabolism, loss of VHL function and accumulation of HIF-1/2α are still
being investigated (55). Moreover, ccRCC cell lines may exhibit higher levels of
oxidative phosphorylation than primary ccRCC cells (153). Establishing a more concrete
relationship between loss of mitochondrial oxidation, VHL deficiency and accumulation
of H2S is a priority. Measurement of H2S in primary ccRCC cells using the intracellular
fluorescent probe and live-cell imaging would be ideal given the high throughput nature
of the assay. DNA, RNA and protein analysis of these primary cells would then allow for
determination of VHL mutation status, HIF-1/2α expression profiling and metabolic
profiling, each of which could be correlated against the level of H2S in each sample.
Treatment of these primary cells with inhibitors of endogenous H2S production and
subsequent viability, proliferation, and metabolic assays would provide a more
translational approach than the one used here.
The CAM angiogenesis assay used here provided good evidence that inhibition of
endogenous H2S production can reduce microvascular density of ccRCC tumours. The
logical next step in investigating the role of H2S in ccRCC vascularization is xenografting
human cell lines into immune-deficient mice and determining whether similar effects are
observed. Furthermore, this more complex mammalian system will provide insight into
the true adverse effects that systemic inhibition of H2S production has on the host.
Inhibitors of H2S production have been used to treat subcutaneously-xenografted colon
cancer tumours in mice, although inhibitors were injected subcutaneously and not
intravascularly (131). Given the immunogenic nature of ccRCC (40), and the prominent
role of H2S in immunology and renal inflammation (78), it would be interesting to
evaluate how this treatment changes the interaction between the tumour and the host
immune system. There are commercially available, mouse-derived renal cancer cell lines
that would make this possible.
Mouse models have also been developed to evaluate spontaneous metastasis of renal
cancer cells after orthotopic implantation within the kidney, which would facilitate
investigation of the role that H2S plays in metastasis (154). Prior to investigating the
involvement of H2S in metastatic progression in vivo, it would be best to first investigate
the involvement of H2S in ccRCC migration and expression of epithelial-mesenchymal
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transition (EMT) markers. H2S has been shown to increase the migration of endothelial
cells (108) and colon cancer cells (131), and has also been shown to induce expression of
EMT markers COX-2 and MMP2 in liver cancer cells (155). Addition of ‘antimetastatic’ to the list of anti-tumourigenic properties that this therapy has shown to
possess would increase the likelihood of its clinical efficacy.
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5. Conclusions
From this body of work, the following conclusions can be drawn:
1. Levels of H2S are increased in ccRCC cell lines lacking a functional copy of the
VHL tumour suppressor.
2. Increased levels of H2S in ccRCC cell lines are not due to increased expression of
the H2S-producing enzymes CBS, CSE and MPST. Furthermore, these enzymes
are not upregulated in human ccRCC tumours.
3. Targeting endogenous H2S production in ccRCC cell lines using inhibitors results
in decreased cell proliferation, metabolism and survival when compared to nonmalignant renal epithelial cells.
4. Systemic inhibition of endogenous H2S production in chick embryos can reduce
the vascularization of VHL-deficient ccRCC xenografts.
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